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ABSTRACT 
Cefepime is a fourth-generation cephalosporin approved by the FDA in 1996 
(Barlow 2003).  Few instances of cefepime resistance have been reported.  This research 
used directed molecular evolution involving error-prone rolling circle amplification on 
plasmids containing the beta-lactamase gene designated as bla-cmy-2.  This gene is 
believed to be responsible for the majority of the nontyphoidal Salmonella enterica 
cephalosporin antimicrobial resistance in this country (Daniels 2007).  Plasmids were 
removed from Salmonella and Yersinia bacteria exhibiting resistance to the following 
third-generation cephalosporins: ceftiofur, cefotaxime, cefixime, ceftriaxone, and 
ceftazidime.  The goals of this research were to identify bla-cmy-2 mutations that confer 
cefepime resistance.  Error-prone rolling circle amplification yielded a mutation encoding 
cefepime resistance.  This mutation altered the secondary structure in the region of the H-
10 helix, which is a part of the catalytic site for extended-spectrum beta-lactamases.  In 
summary, bla-cmy-2 mutations are sources of resistance for extended-spectrum beta-
lactamases that can use fourth-generation cephalosporins as substrates in E. coli. 
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CHAPTER 1. INTRODUCTION 
Review of beta-lactam antimicrobials 
One of the first discovered antimicrobial agents was penicillin, which was isolated 
by Alexander Fleming in 1928 from Penicillium notatum.  Penicillin was later discovered 
to be a beta-lactam drug.  Beta-lactam drugs contain a four-member ring as part of their 
structure.  This ring is referred to as the beta-lactam ring (Neu 1986).  The bactericidal 
mode of action of beta-lactams is to bind to and inhibit penicillin-binding proteins 
(PBPs).   
PBPs participate in the synthesis of the bacterial cell wall by catalyzing the 
maturation and cross-linking of peptidoglycans (Atrih 1999).  PBPs are located on the 
outer surface of the cytoplasmic membranes of bacteria (Chalut 2001).  Although all 
bacteria have these PBPs, there are significant species-dependent variations in their 
number and morphology.  These variations lead to different levels of affinity between 
species of bacteria for beta-lactam antibiotics (Moya 2009).  PBPs have several known 
enzymatic functions including peptidoglycan transpeptidase activity.  The enzymatic 
function of peptidoglycan transpeptidase is to cross-link the peptidoglycans to form the 
bacterial cell wall (Mainardi 2005).  PBPs are essential for cell survival and are the target 
of beta-lactam antibiotic therapy.  Other enzymatic functions of PBP include 
carboxypeptidase and endopeptidase activities.  Carboxypeptidase function is not fully 
understood and may be non-essential for bacterial life (Nelson 2001, Ghosh 2008).  
However, there is research indicating that the enzymatic functions of carboxypeptidase 
and endopeptidase may be responsible for the overall cell shape (Meberg 2004).  When 
PBPs are identified in bacteria, they are labeled or numbered by their size, which can 
range from 35 to 120 kDa (Peddi 2009).  Using their size, they are divided into low-
molecular-mass and high-molecular-mass PBPs (Peddi 2009).  The high-molecular-mass 
PBPs are more likely to have peptidoglycan transpeptidase activity (Peddi 2009).  
Several different families of structures are referred to as beta-lactams antibiotics.  
Note the following structures: 
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               _______________________________ 
 
Figure 1.  Penicillin, the first beta-lactam drug discovered, consists of a beta-lactam 
ring and a thiazolidine ring.  Side chains attach at “R.”  
 
             _________________________________ 
 
 
Figure 2.  Carbapenems consist of a beta-lactam ring and a modified thiazolidine 
ring.  Carbapenems have three side chains: R1, R2, and R3.  
         _________________________________ 
 
 
Figure 3.  Monobactams consist of a solo beta-lactam ring and one side chain, R1. 
          _________________________________ 
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Figure 4.  Cephalosporins consist of a beta-lactam ring and a dihydrothiazine ring.  
Cephalosporins have two side chains: R1 and R2. 
 
The cephalosporin group of beta-lactams was the focus of this research, and thus, they 
will be emphasized henceforth. 
 
 
Review of Cephalosporins 
 Cephalosporin antibiotics originated with the 1945 discovery of Cephalosporium 
acremonium in the sewers of the Mediterranean island of Sardinia (Abraham 1979).  
From this fungus, dozens of antimicrobial agents have arisen. 
There are five generations of cephalosporin antibiotics currently described.  The 
synthesis of many of them starts with a 7-aminocephalosporanic acid (7-ACA) molecule 
(Nigam 2005). 
 
Figure 5.  7-ACA.   
 
 7-ACA is synthesized by deacylation of cephalosporin-C (Nigam 2005).  
Cephalosporin-C was the first cephalosporin isolated.  The cephem nucleus consists of a 
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beta-lactam ring and a dihydrothiazine ring.  Side chains that impart individual and 
unique bactericidal spectral and beta-lactamase resistance characteristics are attached at 
C-3 and C-7 (Neu 1986).  The generational designation of different cephalosporins 
reflects the spectrum of activity.  The first-generation cephalosporin spectrum includes 
gram-positive organisms (Merk 2009).  The second-generation cephalosporin spectrum 
includes fewer gram-positive organisms and more gram-negative organisms than the 
first-generation cephalosporin spectrum.  The second-generation drugs also have some 
activity against anaerobes (Merk 2009).  The third- and fourth-generation cephalosporin 
spectra include more gram-negative organisms and fewer gram-positive organisms than 
the second-generation cephalosporin spectrum.  They are recommended clinically for 
polymicrobial infections caused by gram-negative bacilli and gram-positive cocci (Merk 
2009).  Table 1 summarizes the generation of cephalosporins including examples and 
spectra. 
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Table 1.   Drugs from the four generations of cephalosporins and their spectra of 
activity 
      
First-generation 
cephalopsorins   Spectrum      
Cefacetrile  Gram-positive:    
Cefadroxil  Penicillinase-producing   
Cephalexin  methicillin-susceptible staphylococci   
Cefaloglycin  and streptococci    
Cefalonium       
Cefaloridine  Gram-negative:    
Cefalotin  Including Proteus mirabilis,   
Cefapirin  some Escherichia coli, and   
Cefatrizine  Klebsiella pneumoniae   
Cefazaflur       
Cefazedone       
Cefazolin       
Cefradine       
Cefroxadine       
Ceftezole       
        
Second-generation 
cephalosporins  Spectrum     
Cefaclor  Gram-positive:    
Cefonicid  Less than first-generation cephalosporins 
Cefprozil     
Cefuroxime  Gram-negative:    
Cefuzonam  In addition to first-generation spectrum 
Cefmetazole  Haemophilus influenzae,     
Cefotetan  Enterobacter aerogenes,   
Cefoxitin  and some Neisseria    
        
        
 
 
Third-generation 
cephalosporins  
 
 
Spectrum     
Cefcapene  Gram-positive:    
Cefdaloxime  Some third-generation drugs are   
Cefdinir  less than first- and second-   
Cefditoren  generation cephalsprins  
Cefetamet       
Cefixime  Gram-negative:  
Cefmenoxime  3rd generation have broader spectrum then 1st  
Cefodizime  or 2nd generation cephalsporins;   
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Table 1 continued 
 
Cefotaxime  Including E. coli, Klebsiella, penicillin-resistant  
Cefovecin  N. gonorrhoeae and meningitis caused by, 
Cefpimizole  pneumccci, meningococci, H. influenzae 
Cefpodoxime       
Cefteram       
Ceftibuten       
Ceftiofur       
Ceftiolene       
Ceftizoxime        
Ceftriaxone        
Cefoperazone        
Ceftazidime       
        
Fourth-generation 
cephalosporins  Spectrum     
Cefclidine  Gram-positive:    
Cefepime  Similar to first-generation cephalosporins 
Cefluprenam       
Cefoselis  Gram-negative:    
Cefozopran  Increase over all spectrum, including CNS infections  
Cefpirome  and Pseudomonas aeruginosa   
Cefquinome       
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Table 2.  Cephalosporin drugs with similar and dissimilar side chains at C-7 
 
 
Cephalosporin drugs with similar side chains at C-7
  Group 1  Group 2  Group 3  
Generations ↓  ↓  ↓  
First  Cefalotin  Cephradine   
    Cephalexin   
    Cefadroxil    
        
Secon
d  Cefoxitin  Cefaclor    
        
Third      Ceftizoxime 
      Cefotaxime 
      Cefpodoxime 
      Ceftriaxone 
        
Fourth      Cefepime  
      Cefpirome  
Cephalosporin drugs with dissimilar side chains at C-7
        
Generations       
First Cefazolin       
        
Secon
d Cefotetan       
 Cefuroxime      
 Cefprozil       
 Cefmetazole      
        
Third Cefoperazone      
 Cefdinir       
 Cefditoren       
 Cefixime       
 Ceftibuten       
 Ceftazidime      
        
        
(source: Michael E. Pichichero, MD; Cephalosporins can be prescribed safely for penicillin-allergic 
patients; Journal of Family practice Feb 2006. vol.55, No.2) 
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Table 3.  Cephalosporin drugs with similar and dissimilar side chains at C-3 
ibidCephalosporin drugs with similar side chains at C-3
  Group 1 Group 2 Group 3 Group 4 Group 5 Group 6 
Generations ↓ ↓ ↓ ↓ ↓ ↓ 
First  Cefadroxil      
  Cephalexin     
        
Second   Cefmetazole  Cefuroxime 
   Cefotetan   Cefoxitin  
        
Third   Cefoperazone Cefotaxime Ceftibuten  Cefdinir 
    Cefalotin Ceftizoxime Cefixime 
        
        
        
Fourth        
        
ibidCephalosporin drug with dissimilar side chains at C-3
        
Generations       
First Cefazolin       
        
Second Cefprozil       
 Cefaclor       
        
Third Cefpodoxime      
 Ceftibuten       
 Ceftriaxone      
 Ceftazidime      
        
Fourth Cefepime       
 Cefpirome       
        
 
Cephalosporin bactericidal activity results from a similarity in the structure of the 
beta-lactam ring and the D-alanyl-D-alanine extremity of nascent peptidoglycan (Mainardi 
2005).  This similarity in structure creates the competitive inhibition of PBPs, which 
facilitate the maturation and linking of peptidoglycans in bacterial cell wall synthesis 
(Mainardi 2005).  This results in the inhibition of bacterial wall synthesis.  Later 
generations of cephalosporins target gram-negative bacteria more than the gram-positive 
bacteria.  
The third-generation cephalosporins used in this research include ceftiofur, 
cefotaxime, cefixime, ceftriaxone, and ceftazidime (Figs 6–11).  Large side chains similar 
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to oxyimino moieties may be responsible for some of the increased resistance third-
generation cephalosporins exhibit to enzymatic destruction by beta-lactamases. 
 
Figure 6.  Oxyimino-acetic acid.  
 
 
Figure 7.  Ceftiofur sodium.  
 
 
Figure 8.  Cefotaxime. 
 
 
Figure 9.  Cefixime. 
 
Cefixime is considered the first third-generation oral cephalosporin (Roche 1989).  
The structural modification that enabled per os administration was the addition of a vinyl 
group at C-3 (Roche 1989).  The third-generation cephalosporin antimicrobial 
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characteristics possessed by cefixime result from an aminothiazole ring and an R-
oxyimino group at C-7 (Roche 1989).  Cefixime has been clinically recommended for the 
treatment of lower respiratory tract, ear-nose-throat, and urinary tract infections (UTIs) 
(Roche 1989).  Cefpodoxime is the only other oral third-generation cephalosporin, and it 
is structurally similar to cefixime. 
 
 
 
Figure 10.  Ceftriaxone. 
 
Ceftriaxone has an oxyimino group at C-7 and a thiadiazolylthiomethyl group at 
C-3 (Reiner 1986).  Ceftriaxone has a long half-life of 8 h, and it was the first beta-lactam 
recommended for once-a-day administration (Reiner 1986). 
 
 
Figure 11.  Ceftazidime. 
 
The addition of a quaternary ammonium group at the C-3′ position is the 
modification that distinguishes third-generation and fourth-generation cephalosporins 
(Garau 2008).  Fourth-generation cephalosporins are zwitterionic compounds (Garau 
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2008).  This implies electrical neutrality and polar characteristics (a + end and a − end).  
These attributes enables fourth-generation cephalosporins to rapidly penetrate the outer 
membrane of gram-negative bacteria (Garau 2008).  In addition, research has 
demonstrated that beta-lactamase enzymes have lower affinity for fourth-generation 
cephalosporins (Garau 2008).  This low affinity for fourth-generation cephalosporins 
results in a lower rate of hydrolysis by these enzymes.  This fact, together with rapid 
penetration into the cell, results in a decrease in the rate at which bacteria become 
resistant to fourth-generation cephalosporins (Giamarellou 1999). 
 
Figure 12.  Cefepime -fourth.   
The side chains that distinguish cefepime are an aminothiadiazolyl group at C-7′ 
and a quaternary ammonium at position-3 (Watanabe 1996). 
Cefepime received FDA approval in 1996 (Barlow 2003).  Structurally, it is most 
similar to a third-generation cephalosporin, ceftazidime (Barlow 2003).  These two 
cephalosporins have noticeably different mechanisms of resistance and susceptibility to 
bacteria.  As would be expected, there are many examples in which cefepime is more 
resilient than earlier cephalosporins.  The greater spectrum of activity of cefepime 
compared to that of ceftazidime may result from factors including a significantly lower 
affinity for plasmid-mediated AmpC β-lactamases than ceftazidime and that ceftazidime 
is hydrolyzed by β-lactamases to a greater degree than cefepime (Endimiani 2008). 
Cefepime was approved for the treatment of moderate to severe infections 
including pneumonia, uncomplicated and complicated UTIs, soft tissue and skin 
infections, intra-abdominal infections, and febrile neutropenia (Endimiani 2008).  A low 
frequency of spontaneous resistance mutations is described for cefepime (Endimiani 
2008).  This description resulted from research in which wild-type P. aeruginosa strains 
required an average of 30 passages of cefepime-selected isolation for resistance to 
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develop, in comparison to 15.2, 18.0, and 3.5 passages for cefpirome, ceftazidime, and 
cefotaxime, respectively (Endimiani 2008, Carsenti-Etesse 2001).  
The mechanisms by which cefepime resistance has developed have rarely been 
bacteria-specific.  Enterobacteriaceae such as E. coli and Klebsiella species have 
infrequently developed resistance by either producing class A extended-spectrum β-
lactamases (ESBLs) or class A or B carbapenemases (Endimiani 2008).  P. aeruginosa 
usually acquire cefepime resistance through a combination of tactics.  First, P. 
aeruginosa hyper-produce class C chromosomal enzymes, e.g., AmpC.  Second, P. 
aeruginosa will upregulate their efflux pumps and remove cefepime (Endimiani 2008).  
To a lesser extent, there are isolated geographic reports of cefepime-resistant P. 
aeruginosa producing metallo-β-lactamases such as CTX-M (Endimiani 2008).  
Acinetobacter baumannii has exhibited cefepime resistance.  There are three mechanisms 
attributed to A. baumannii resistance to cefepime: hyper-production of chromosomal 
OXA-51/69-like carbapenemases, activation of efflux pumps such as AdeABC, and porin 
exchange (Endimiani 2008). 
 
Review of β-lactamases 
The hope of discovering a panacea felt after the discovery of the antimicrobial 
action of beta-lactam drugs was soon dashed by the appearance of bacteria possessing 
innate resistance.  The means of resistance to beta-lactam drugs by these bacteria was 
soon discovered to be the enzymatic destruction of the drugs by a number of different 
enzymes called beta-lactamases.  In keeping with the discovery of new forms of beta-
lactam antimicrobial drugs, bacteria have employed or evolved beta-lactamase enzymes 
that eliminate them. 
The first identification of a beta-lactam-destroying enzyme was made in 1940 
(Sutherland 1990).  These enzymes are as a group referred to as beta-lactamases.  The 
mechanism by which beta-lactamases destroy beta-lactam antimicrobials is to hydrolyze 
the beta-lactam ring (Bush 1988, Mainardi 2005).  Once the ring is destroyed, their 
antimicrobial activity is lost.  In an attempt to overcome the effects of this enzyme, a 
screening for naturally occurring beta-lactamase inhibitors was performed (Sutherland 
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1990).  From this research, it was found that clavulanic acid from Streptomyces 
clavuligerus is a beta-lactamase inhibitor (Sutherland 1990).  
 
Figure 13.  Clavulanic acid.  
From the structure in Figure 13, it is clear that clavulanic acid is related to the 
beta-lactam family (Kim 2009).  It, however, has little or no antimicrobial activity (Kim 
2009).  It functions as a competitive inhibitor of beta-lactamase (Kim 2009).  One of the 
criteria used to categorize different beta-lactamases is whether the beta-lactamase is 
inhibited by clavulanic acid.  Other beta-lactamase inhibitors have been discovered 
including sulbactam and tazobactam (Hedburg 1992).  However, their spectrum of 
activity is not used in the classification of beta-lactamases (Bush 1995). 
 The susceptibility of beta-lactamase to clavulanic acid, together with the group of 
beta-lactams being eliminated and the molecular class of the enzyme, is used as a 
criterion for classification (Bush 1995).  There are three major groupings of beta-
lactamases (Bush 1995).  Group 1 includes enzymes labeled cephalosporinases; this 
group hydrolyzes cephalosporins and exhibits resistance to clavulanic acid (Bush 1995).  
Group 2 includes penicillinases, cephalosporinases, and broad-spectrum beta-lactamases 
that can potentially eliminate penicillins, cephalosporins, and other beta-lactam groups 
(Bush 1995).  Group 2 beta-lactamases are generally sensitive to clavulanic acid (Bush 
1995).  Group 3 beta-lactamases include metallo-beta-lactamases and can eliminate 
penicillins, cephalosporins, and carbapenems (Bush 1995).  Group 3 enzymes are 
resistant to clavulanic acid (Bush 1995). 
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Table 4.  Classification schemes for bacterial β-lactamases 
Bush-
Jacoby- 1989 Bush  Richmond-  Mirsuhashi- Molecular Preferred   Inhibited by Representative  
Medeiros  Group (44) Sykes Inoue Class  Substrates  CA EDTA enzymes  
Group  Class (253) Type (194)a (2, 121, 132)      
1 1 Ia, Ib, Id CSase C Cephalosporins - - 
AmpC enzymes  
bacteria;  
         from gram-negative 
         MIR-1  
2a 2a 
Not 
included PCase V A Penicillins  + - Penicillinase from  
         gram-positive  
         bacteria  
2b 2b III PCase I A Penicillins,   + - TEM-1, TEM-2,  
     Cephalsporins    SHV-1  
2be 2b’ 
Not 
included   CXase A Penicillins,    + - TEM-3 to TEM-26,   
  except K1    narrow spectrum,    SHV-2 to SHV-6, 
  in class IV   and    Klebsiella oxytoca K1 
     
extended 
spectrum     
     cephalosporins,     
     
 
monobactams      
2br 
Not 
included 
Not 
included Not included A Penicillins  ± - TEM-30 to TEM-36,  
         TRC-1  
2c 2c II, IV PCase IV A Penicillins,   + - PSE-1, PSE-3, PSE-4 
     carbenicillin      
2d 2d V PCase II,  D Penicillins,  ± - OXA-1 to OXA-11,  
   PCase III   cloxacillin    PSE-2 (OXA-10) 
2e 2e Ic CXase A Cephalosporins + - 
Inducible 
cephalsporinases  
         from Proteus vulgaris 
2f 
Not 
included 
Not 
included Not included A Penicillins,    + - 
NMC-A from  Sme-1 
from  
     cephalsporins,    Enterobacter cloacae, 
     carbapenems    Serratia marcescens 
3 3 
Not 
included Not included B Most β-lactams,   - + I1 from Xanthomonas   
     including    
maltophilia, CcrA 
from 
     carbapenems    Bacteroides Fragilis  
4 4 
Not 
included Not included NDa Penicillins  - ? Penicillinase from  
         Pseudomonas cipacia 
           
a-Csase, cephalsporinase; Pcase, penicilinase; CXase, cefuroxime 
hydrolyzing β-lactamase.       
b-CA, clavulanic acid          
c-ND, not determined          
(Source: reproduced from Bush K, Jacoby GA, Medeiros AA.1995. "A functional 
classification scheme for beta-lactamases and its correlation with molecular structure." 
Antimicrob Agents Chemother. 1995;39: 1211–33) 
This research involved a group 1 beta-lactamase termed AmpC-bla-cmy-2. 
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 Interestingly, the first beta-lactamase enzyme discovered was an AmpC enzyme 
(Jacoby 2009).  The genetic sequence of AmpC beta-lactamases from E. coli was 
presented in research in 1981 (Jacoby 2009).  Since the AmpC sequence of E. coli was 
first identified, similar sequences with beta-lactamase activity have been identified and 
cataloged in different genera and species (Jacoby 2009).  However, variability in AmpC 
beta-lactamase genes has been identified even within species (Jacoby 2009).  AmpC beta-
lactamases can hydrolyze the beta-lactam ring of penicillins but are more effective at 
eliminating cephalosporins (Jacoby 2009).  One of the factors attributed to AmpC activity 
is its high affinity for beta-lactams (Jacoby 2009).  AmpC is classified as a Class C 
enzyme (Jacoby 2009).  Class C enzymes have the advantage of a wider active site for 
catalysis (Jacoby 2009).  This fact is also believed to aid in the increased ability of AmpC 
to deal with cephalosporins possessing large side chains (Jacoby 2009). 
 One source stated that a beta-lactamase was first attributed to a sequence on a 
plasmid in 1976; however, no material remains from this experiment to verify its validity 
(Phillippon 2002).  Subsequently, it has been confirmed that sequences that lead to beta-
lactamase synthesis can be transferred between bacteria in plasmids.  One grouping of 
these plasmid-based AmpC beta-lactamases has been classified as cmy (Jacoby 2009).  
AmpC bla-cmy-2 was used in this research (Jacoby 2009). 
 
Review of Plasmids 
Bacteria have several types of DNA.  One type is referred to as plasmids.  
Plasmids are circular pieces of DNA that can be transferred from one bacterial cell to 
another, thereby spreading antibiotic resistance (Berg 2007).  Plasmids are spread 
between bacteria in two known methods.  The first method is by a process referred to as 
“bacterial conjugation,” which involves the pilus transfer of genes (Nakano 2004).  A 
second method in which a plasmid can be transferred from one bacterium to a second is 
transformation.  In the laboratory, the naturally occurring process of transformation has 
been elaborated to involve electrocompetent cells and chemically competent cells 
(Nakano 2004).  Cell transformation using electrocompetent cells and chemically 
competent cells were used in this research. 
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Review of Bla-Cmy-2 
The essence of this research is centered on whether a particular beta-lactamase 
can be induced to confer cefepime resistance to bacteria.  This beta-lactamase is cmy-2.  
The cmy-2 enzyme is of particular interest, as it hydrolyzes cephalosporin beta-lactam 
drugs.  In addition, bla-cmy-2 has been found on plasmids.  This fact means 
cephalosporin resistance can be transformed between bacteria.  This is believed to be 
responsible for the majority of the nontyphoidal Salmonella enterica cephalosporin 
antimicrobial resistance in this country (Daniels 2007).  The sequence of bla-cmy-2 
found in plasmids is thought to have originated from the chromosomal DNA of 
Citrobacter freundii (Daniels 2007).  The bla-cmy-2 sequence in plasmids consists of 
1146 nucleotides, leading to 381 amino acids (Bauernfeind 1996).  Cmy-2 is a class C 
beta-lactamase (Bauernfeind 1996).  Transcription of plasmid-mediated bla-cmy-2 is not 
activated by a catabolic operon, as it does not contain the AmpR sequence (Nakano2004).  
There are references suggesting that bla-cmy-2 transcription may be activated in response 
to the promoter region ISEcp1 or ISEcp1B (Lartigue 2006). 
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Figure 14.  Nucleotide sequence of blaCMY-2 
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(source: reproduced from A Bauernfeind, I Stemplinger, R Jungwirth and H 
Giamarellou; Characterization of the plasmidic beta-lactamase CMY-2, which is 
responsible for cephamycin resistance; Antimicrobial Agents and Chemotherapy, Jan 
1996, 221–224, Vol 40, No. 1) 
 
Review of MnCl2 interference with DNA polymerase 
A 2004 article describing the use of manganese in conjunction with error-prone 
rolling circle amplification states that manganese ions reduce the fidelity of DNA 
polymerase by biasing the deoxyribonucleotide concentration (Fujii 2004).  Possible 
causes for this reduced fidelity may result from the observation that in the presence of 
manganese, the dissociation constant has been reported to decrease 30-fold “such that 
there is little regard for the instructions provided by the templating base” (Frank 2007).  
A second possible cause may be that the proofreading capability of DNA polymerase is 
compromised, which would result in unrepaired mutations.  There are three subunits of 
DNA polymerase III, alpha, theta, and epsilon, with the latter being responsible for the 
exonuclease proofreading activity (Hamdan 2002).  The efficiency of hydrolysis required 
for exonuclease proofreading activity is altered on the basis of the divalent metal present, 
namely magnesium versus manganese (Hamdan 2002).  
 
Review of rolling circle amplification 
Rolling circle amplification or rolling circle replication is the natural process by 
which plasmids and some circular viruses are synthesized (Dean 2001).  In the 1990s, this 
natural process had been modified to make it a means of laboratory circular DNA 
amplification (Fuji 2006).  Steps in this process include adding primers to an existing 
circular piece of DNA (Dean 2001).  These primers are resistant to the exonuclease or 
DNA repair mechanism of the DNA polymerase used (Dean 2001).  The DNA 
polymerase used (psi29 DNA polymerase) is highly processive or strongly attached to the 
template strand named (Dean 2001).  The DNA polymerase attaches at the exonuclease 
resistant primers on the circular DNA and begins to assemble nucleotides (Dean 2001).  
As the polymerase reads the circular DNA template, it reaches the next primer (Dean 
2001).  Other less processive DNA polymerases would stop at this point, but the psi29 
DNA polymerase stays attached to the template and continues to assemble nucleotides 
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until the available nucleotides for assembly are depleted (Dean 2001).  The result is a 
long double-strand of nucleotide repeats of the circular DNA and the primer (Dean 2001).  
Additional psi 29 DNA polymerases attach at these new primers and start to assemble 
nucleotides of only the synthesized strand (Dean 2001).  This leads to an exponential 
increase in the repeated strands (Dean 2001).  The repeated strands are referred to as 
concatemers (Fuji 2006).  Concatemers reform into a circle by means of intramolecular 
homologous recombination (Fuji 2006). 
 
Figure 15.  Illustration of rolling circle amplification. 
 
Aims of the project 
Bacterial resistance to cefepime, a fourth-generation cephalosporin, has 
infrequently been documented.  The aim of this research is to use directed molecular 
evolution to predict possible mutations to the beta-lactamase cmy-2 that will confer 
bacterial resistance to cefepime and possibly other fourth-generation cephalosporins. 
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This research involved the use of error-prone rolling circle amplification to 
modify the genetic sequence of AmpC Bla-Cmy-2 to anticipate possible mutations 
resulting from natural evolution that will enable it to hydrolyze fourth-generation 
cephalosporins.  In this pursuit, the AmpC-carrying plasmids that had displayed third-
generation cephalosporin resistance were isolated from S. enterica var Typhimurium 
DT104 strains 1441, 3453, 5317, 7330, 7599, 8501, and 9853, Salmonella 968, and S. 
enterica var St Paul.  Mutagenesis by error-prone rolling circle amplification was 
performed on these plasmids.  Electrotransformation of these plasmids into E. coli, 
Salmonella, Yersinia, and Proteus was followed by the sensitivity testing of a fourth-
generation cephalosporin, cefepime, at its breakpoint. 
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CHAPTER 2. MATERIALS AND METHODS 
Bacteria screening sensitivity in 96-well plates 
Ceftiofur, cefotaxime, cefixime, ceftriaxone, cefovecin, cefepime, and cefozopran 
were attained from commercial sources.  Breakpoints were established by CLSI (REF).  
The following strains were used: S. enterica var Typhimurium DT104 strains 196, 247, 
799, 1441, 3673, 3453, 4430, 5852, 5317, 5221, 7599, 7356, 7330, 8151, 8501, 9853, and 
10452, Salmonella 968, and S. enterica var St Paul. 
Antibiotic sensitivity was assayed using 96-well plates.  Bacteria were exposed to 
the antibiotics at the concentrations given below in lysogeny broth (LB).  Incubation 
occurred for 24 h in an orbital shaker at 37°C. 
ceftiofur - 1, 2, 4, 8, 16, 32, 64, 128 µg/ml 
cefotaxime - 4, 8, 16, 32, 64, 128, 256, 512 µg/ml 
cefixime - 1, 2, 4, 8, 16, 32, 64, 128 µg/ml 
ceftriaxone - 1, 2, 4, 8, 16, 32, 64, 128 µg/ml  
cefovecin - 1, 2, 4, 8, 16, 32, 64, 128 µg/ml 
cefepime - 2, 4, 8, 16, 32, 64, 128, 256 µg/ml 
cefozopran - 1, 2, 4, 8, 16, 32, 64, 128 µg/ml 
 
Cosmid removal–Qiagen large-construct kit 
Using the Qiagen large-construct kit, cosmids from the following microbes were 
removed: S. enterica var Typhimurium DT104 strains 1441, 3453, 5317, 7330, 7599, 
8501, and 9853, Salmonella 968, S. enterica var St Paul, and Yersinia 968.  In addition to 
the Qiagen large-construct kit, adenosine triphosphate (ATP) disodium salt was 
purchased.  The following procedure was performed individually on each of the above 
bacteria.  Bacteria were statically grown in 500 ml of commercially purchased LB.  After 
24 h, LB was transferred into 10–50-ml falcon tubes and centrifuged at 4100 rpm (limit 
of centrifuge) for 15 min.  Supernatant was decanted, and tubes left inverted to drain.  
Ten milliliters of buffer P1with RNAse A were used to re-suspend all 10 bacterial cell 
pellets (RNase A will digest any RNA present during the alkaline lysis, which is the next 
step).  Twenty milliliters of Buffer P2 were next added.  Buffer P2 contains 200 mM 
NaOH and 1% sodium dodecyl sulfate (SDS; NaOH lyses the bacterial cells, SDS aids in 
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lysis by solubilizing the phospholipid and protein components of the cell membrane).  
After 5 min, 20 ml of chilled buffer P3 were added (buffer P3 is acidic potassium acetate; 
its role is to neutralize the lytic action of buffer P2).  After 10 min of incubation on ice, 
the suspension was centrifuged at 4100 rpm for 30 min.  Following centrifugation, the 
lysate was filtered through a supplied filter (this filtering was done to remove any 
particulate material that may hinder complete exonuclease action in subsequent steps).  
The DNA was then precipitated from the lysate by adding 36 ml of isopropanol.  This 
filtered lysate was then centrifuged at 4100 rpm for 30 min.  Following centrifugation, 
the supernatant was carefully decanted.  The DNA pellet was then washed by adding 2.5 
ml of 70% ethanol to each tube, followed by centrifugation at 4100 rpm for 15 min and 
careful decantation.  This step was repeated.  Tubes were then air-dried for 3 min.  The 
resulting DNA pellet dissolved in 4.75 ml of buffer EX.  The DNA was then incubated 
with 200 µl of ATP-dependent exonuclease and 300 µl of ATP solution.  This step 
resulted in digestion of all types of DNA other than super-coiled DNA.  The tube was 
placed in a water bath at 37°C for 1 h.  Then, its content containing the digested DNA 
and the intact tightly coiled DNA was transferred to a sterile tube.  Ten milliliters of QS 
buffer then were added to this sterile tube.  A Qiagen-tip 500 elution column was primed 
with 10 ml of QBT buffer.  The tube containing the DNA and QS buffer was then applied 
to the elution column and allowed to run through the column.  The DNA is theoretically 
in the column, and 30 ml of buffer QC were then applied to the column to rinse away any 
impurities other than the intact tightly coiled DNA.  The elution column was placed over 
a fresh sterile tube, and 15 ml of buffer QF prewarmed to 65°C were applied.  The intact 
DNA was eluted by buffer QF.  Isopropanol (10.5 ml) was added, and the tube was 
centrifuged at 4100 rpm for 30 min.  Supernatant from the pellet containing only intact 
tightly coiled DNA was carefully decanted.  Five milliliters of 70% ethanol were added, 
and the tube was centrifuged at 4100 rpm for 15 min.  Supernatant was carefully decanted 
from the DNA pellet, which was dried for 10 min.  One hundred microliters of 
diethylpyrocarbonate H2O were added to re-dissolve the pellet. 
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Rolling circle amplification w MnCl2-GE Healthcare Life Science  
illustra TempliPhi 100/500 DNA Amplification Kit 
Cosmids from the following bacteria underwent rolling circle amplification with 
MnCl2: Yersinia 968, Salmonella 968, and S. enterica var Typhimurium DT104 strains 
1441, 3453, 5317, 7330, 7599, and 9853.  A GE Healthcare Life Science illustra 
Templiphi 100/500 DNA Amplification Kit was used in this project.  The amplification 
kit consists of three components: a sample buffer, a reaction buffer, and an enzyme mix.  
The sample buffer consists of DNA polymerase primers.  These primers are resistant to 
the exonuclease proofreading activity of DNA polymerase.  Their function is to provide 
an attachment and initiation site for DNA polymerase.  The reaction buffer consists of 
salts and free deoxynucleotides in a solution with a pH that supports DNA polymerase 
activity.  The deoxyribonucleotides are the nucleotides that will be used to assemble new 
strands.  The final part of the kit is the enzyme mix.  The enzyme mix has the highly 
processive DNA polymerase psi 29 and also contains more random hexamers.  
Each of the cosmids from the aforementioned bacteria was individually amplified 
in the following manner.  Five microliters of the sample buffer were placed in the 
reaction tube followed by the addition of 0.5 µl of the individual bacterial cosmid.  The 
reaction tube was then sealed and heated to a temperature of 95°C for 3 min, followed by 
cooling to 4°C.  In a second tube, 5 µl of the reaction buffer and 0.2 µl of the enzyme mix 
were combined.  To this was added 1 µl of 1.5 mM MnCl2.  The two reaction tubes were 
placed on ice for 5 min, and then their contents were combined.  This combination was 
then kept at 30°C for 18 h (by this time, all of the deoxyribonucleotides are depleted).  
The reaction tube was then heated to 65°C for 10 min and then cooled to 4°C.  This was 
done to inactivate the psi29 DNA polymerase. 
 
Electrocompetent cell creation 
The following electrocompetent cells were synthesized: Salmonella, Yersinia, E. 
coli, and Proteus.  Individually, 1 ml of each of the following microbes was added to 1 L 
of LB.  The LB was statically incubated at 30°C for 18 h.  After incubation, 40 ml of 
culture were added to 20–50-ml falcon tubes.  Tubes were centrifuged at 4100 rpm for 5 
min.  The supernatant was decanted, leaving cellular pellets.  Cellular pellets were re-
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suspended in 40 ml deionized H2O.  Tubes were re-centrifuged at 4100 rpm for 5 min.  
Supernatant was decanted, leaving cellular pellets.  Cellular pellets were re-suspended in 
20 ml deionized H2O.  Tubes were re-centrifuged at 4100 rpm for 5 min.  Supernatant 
was decanted, leaving cellular pellets.  Cellular pellets were re-suspended in 1 ml of 40% 
glycerol.  Glycerol-suspended cells were aliquoted into 1-ml microtubes and stored at 
−80°C. 
 
Electrocompetent cell transformation 
Using an electroporator, cosmids that underwent error-prone rolling circle 
amplification were transformed into electrocompetent cells of Salmonella, E. coli, 
Yersinia, and Proteus.  Electrocompetent cells and electroporation cuvettes were stored at 
−80°C.  Electrocompetent cells and cuvettes were transferred from −80°C storage to the 
work bench on ice.  To previously aliquoted 50 µl of electrocompetent cells, 2 µl of 
cosmids from the aforementioned bacteria were added.  This combination was transferred 
into a designated electroporation cuvette.  The cuvette was placed inside an 
electropulsator pre-set at 200 Ω, 2.5 kV, and 25 µF for a 0.2-cm cuvette (Chaveroche 
2000).  Electricity was discharged.  Five hundred-fifty microliters of super optimal broth 
with Catabolite repression (SOC; bacterial nutrient solution) were rapidly added to the 
cuvette.  The contents of the cuvette were transferred back to the original microtube and 
incubated for 2 h.  Following incubation, 200 µl of transformed cells were transferred 
into three wells of a 96-well plates containing 200 µl of cefepime (64 µg/ml).  
 
Electrophoresis 
Electrophoresis was used twice in this project: first to determine whether a 
molecule of the size of the cosmids was present following cosmid removal from the 
bacteria and later determine whether a molecule the size of the desired product was 
present after polymerase chain reaction (PCR).  The size of the expected PCR product is 
known as the sequence assembled by Taq polymerase and is defined by specific primers.  
All supplies used here were commercially purchased.  For this research, 0.5% gel was 
used for our electrophoresis.  Gel was synthesized by combining 0.2 g of agarose with 40 
ml of TAE buffer in a 100-ml Erlenmeyer flask.  Thermal agitation aided in dissolving 
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the agarose.  After dissolution was complete, the liquid was cooled at room temperature 
for 5 min and then transferred to the electrophoresis plastic mold.  One drop of ethidium 
bromide (EtBr) was added.  A well mold was placed in the appropriate slot.  Following 
gel solidification, the DNA sample and corresponding ladder were placed in the 
designated wells.  The cap was placed, and the current was set at 88 V for 45 min.  After 
the allotted time, the gel was examined under ultraviolet light, and the extent of molecule 
migration was determined by the EtBr florescence.  DNA samples were compared to the 
ladder.  Larger molecules migrate slower, whereas smaller molecules migrate faster. 
PCR 
PCR was used in this research to amplify the bla-cmy-2 sequence that conferred 
cefepime resistance.  PCR is a method of amplifying nucleotide sequences utilizing a 
DNA polymerase that has high temperature tolerance.  This is significant because the 
DNA double-strands are melted to allow DNA polymerase (Taq) access to a single-
stranded template.  Two microliters each of the established forward and reverse primers 
were added to 2 µl of the cosmid.  These primers defined the nucleotide sequence for bla-
cmy2.  To this were added 5 µl of Expand™ 10× PCR Buffer, 2 µl of 
deoxyribonucleotides, 2 µl of 2.25 mM MgCl2, 0.5 µl of Taq DNA polymerase, and 35.5 
µl of diethylpyrocarbonate H2O.  The thermal cycling protocol is shown in Table 5. 
 
Table 5.  PCR thermal cycling protocol  
STEP TIME TEMPERATURE CYCLE 
Initial 
Denaturation 2 minutes 94°C 1× 
Denaturation 15 seconds 94°C  
Annealing 1 minute 56°C 25× 
Extension 5 minutes 68°C  
Final Extension 7 minutes 72°C 1× 
 
Denaturation, or melting, of the double strands occurred at 94°C.  Taq polymerase 
attached to the template strand at lower temperatures and produced the nucleotide 
sequences defined by the primers.  The presence of product was confirmed by gel 
electrophoresis. 
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Transformation of plasmids using chemically competent cells 
 The sequence containing the mutated bla-cmy-2, after being amplified using 
PCR, was cloned into a pCR XL-TOPO vector and then transformed into chemically 
competent cells.  To 1 µl of the PCR-amplified sequence were added 3 µl of H2O, 1 µl of 
salt solution, and 1 µl of the pCR-XL-TOPO vector.  This mixture was kept at room 
temperature for 5 min, followed by 5 min on ice.  Independently, 2 µl of 0.5 M β-
mercaptoethanol were added to a vial of TOP10 chemically competent cells.  To this vial, 
2 µl of the aforementioned combination of the PCR product with the vector were added.  
This mixture was placed on ice for 30 min.  The competent cells were then heat-shocked 
at 42°C for 30 s.  Following the heat shock, the vial was placed in ice for 2 min.  Two 
hundred fifty microliters of SOC were added.  Cells were left for 2 h at 37°C under 300-
rpm agitation.  Cells were then streaked onto a agar plate containing ampicillin (the 
ampicillin in the agar prevents the growth of invasive bacteria not possessing the pCR-
XL-TOPO vector containing the operon that confers ampicillin and kanamycin 
resistance).  Following overnight incubation, 30 colonies were selected.  These colonies 
were placed in 1-ml tubes containing 50 µg/ml kanamycin.  Kanamycin was again added 
to the tubes in an effort to prevent the growth of invasive bacteria not possessing the 
pCR-XL-TOPO vector containing the operon that confers kanamycin resistance.  In this 
manner, contaminants or bacteria not expressing the vector with the bla-cmy-2 sequence 
of interest were eliminated. 
After confirming that one plasmid contained the bla-cmy-2 gene, the plasmid 
insert was subjected to DNA sequencing by the DNA Facility at Iowa State University.  
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CHAPTER 3. RESULTS 
Transformation of the bla-cmy-2 sequence-containing plasmids that had 
undergone error-prone rolling circle amplification from the aforementioned bacteria was 
repeated until a strain displayed resistance to cefepime 32 µg/ml.  Mutated plasmids 
underwent transformation into electrocompetent cells of E. coli, Salmonella, Proteus, and 
Yersinia.  This was done in search of a plasmid containing a mutated bla-cmy-2 sequence 
that would confer cefepime resistance.  After repeating this transformation 15 times, a 
bacterium displayed growth at 32 µg/ml.  Electrotransformation of the plasmid from 
Salmonella 968 into E. coli resulted in cefepime resistance of minimum inhibitory 
concentration (MIC) > 64 µg/ml.  The breakpoint of cefepime is 32 µg/ml.  In the initial 
susceptibility test, the original Salmonella 968 had an MIC ≤ 2 µg/ml.  
Sequencing of the bla-cmy2 nucleotide sequence of E. coli/Salmonella 968 
revealed the five mutations listed in Table 6.  
 
Table 6.  Mutations in the bla-cmy-2 sequence conferring cefepime resistance 
Nucleotide Amino Acid Change    
27  Silent     
150  Silent     
180  Silent     
833  277 arginine→leucine non-conserved  
941  313 alanine→valine Conserved  
 
The mutations occurred at nucleotides 27 (silent), 150 (silent), 180 (silent), 833, 
and 941.  Silent mutations do not alter the amino acid sequence of the final protein.  The 
guanine was replaced by thymidine at nucleotide 833 (this resulted in arginine being 
replaced by a leucine at amino acid 277; this is a non-conserved substitution).  The 
cytosine was replaced by thymidine at nucleotide 941 (this resulted in alanine being 
replaced by valine at amino acid 313; this is a conserved substitution).  
The observation that an amino acid at a particular location in a sequence is 
common to all strains or varieties of an organism implies that it is vital to the function 
and survival of that organism. 
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 NUCLEOTIDE SEQUENCE OF WILD TYPE BLA_CMY_2 AND MUTATED 
VARIANT 
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Figure 16.  Nucleotide sequence of wild-type BLA CMY 2 and mutated variant.  
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AMINO ACID SEQUENCE OF WILD TYPE BLA_CMY_2 AND MUTATED 
VARIANT 
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Figure 17.  Amino acid sequence of wild-type BLA CMY 2 and mutated variant.  
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SECONDARY STRUCTURE OF WILD TYPE BLA_CMY_2 AND MUTATED 
VARIANT  
WILD TYPE BLA_CMY-2 
Bla^cmy-2 wt Protein Toolbox List Page 1 
Wednesday, February 16, 2011 4:11 PM 
Key: 
Argos = Argos transmembrane 
vH trns = von Heijne transmembrane 
CFhlx = Chou-Fasman Alpha Helix 
CFsht = Chou-Fasman Beta Sheet 
CFturn = Chou-Fasman Turn 
CFval = Chou-Fasman Structure Value 
CFtype = Chou-Fasman Probable Type 
Pos. AA Argos vH trns CFhlx CFsht CFturn CFval CFtype 
1 M 1.420 -0.600 1.470 0.970 0.317 0.65 H 
2 M 1.168 -0.600 1.390 0.903 0.361 0.65 H 
3 K 1.107 -0.600 1.244 0.886 0.365 0.65 H 
4 K 1.107 -0.600 1.233 0.884 0.358 0.65 H 
5 S 1.076 -0.600 1.181 0.851 0.390 0.65 H 
6 L 1.103 -0.600 1.156 0.841 0.289 0.65 H 
7 C 1.146 -0.600 1.166 0.877 0.307 0.65 H 
8 C 1.190 -0.600 1.176 0.913 0.331 0.65 H 
9 A 1.234 -0.600 1.244 0.923 0.191 0.25 H 
10 L 1.267 -0.600 1.177 0.950 0.201 0.65 H 
11 L 1.286 0.221 1.203 0.973 0.209 0.65 H 
12 L 1.296 0.286 1.161 1.003 0.310 0.65 H 
13 T 1.299 0.303 1.130 1.063 0.352 0.40 H 
14 A 1.288 0.303 1.061 1.053 0.370 0.40 H 
15 S 1.272 0.240 0.994 1.080 0.365 0.65 H 
16 F 1.254 0.117 0.961 1.123 0.328 0.65 H 
17 S 1.231 -0.036 1.027 1.079 0.351 0.65 H 
18 T 1.198 -0.181 1.027 1.079 0.220 0.65 H 
19 F 1.155 -0.272 1.094 1.071 0.228 0.40 H 
20 A 1.099 -0.370 1.117 0.993 0.266 0.65 H 
21 A 1.039 -0.429 1.119 1.030 0.287 0.25 H 
22 A 0.974 -0.460 1.206 0.964 0.304 0.25 H 
23 K 0.912 -0.484 1.234 0.890 0.338 0.25 H 
24 T 0.859 -0.540 1.231 0.876 0.281 0.25 H 
25 E 0.822 -0.605 1.186 0.954 0.247 0.65 H 
26 Q 0.799 -0.636 1.186 0.954 0.243 0.65 H 
27 Q 0.793 -0.682 1.159 0.947 0.224 0.65 H 
28 I 0.800 -0.738 1.179 0.981 0.354 0.65 H 
29 A 0.818 -0.737 1.103 1.087 0.236 0.40 H 
30 D 0.836 -0.706 1.050 1.081 0.298 0.40 H 
31 I 0.856 -0.664 1.006 1.109 0.367 0.65 H 
32 V 0.874 -0.635 0.986 1.074 0.323 0.65 H 
33 N 0.892 -0.602 0.940 1.153 0.388 0.65 H 
34 R 0.905 -0.570 0.910 1.223 0.270 0.85 
35 T 0.910 -0.567 0.846 1.107 0.253 0.85 
36 I 0.913 -0.548 0.901 1.040 0.255 1.10 
37 T 0.917 -0.544 0.983 1.070 0.568 0.85 
38 P 0.912 -0.539 1.027 1.043 0.239 1.10 
39 L 0.902 -0.511 1.114 0.977 0.244 0.85 
40 M 0.892 -0.439 1.157 0.884 0.341 0.85 
41 Q 0.894 -0.371 1.223 0.840 0.229 0.65 
42 E 0.907 -0.325 1.287 0.956 0.245 0.85 
43 Q 0.923 -0.259 1.176 0.901 0.231 0.85 
44 A 0.952 -0.187 1.046 0.894 0.280 0.85 
45 I 0.998 -0.164 1.074 0.919 0.679 0.85 T 
46 P 1.051 -0.176 1.053 0.940 0.259 0.85 T 
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47 G 1.101 -0.204 1.001 1.039 0.272 1.10 T 
48 M 1.137 -0.210 1.001 1.039 0.228 1.10 T 
49 A 1.155 -0.211 0.993 1.044 0.196 0.50 
50 V 1.159 -0.219 1.057 1.160 0.220 0.00 
51 A 1.137 -0.208 1.080 1.207 0.246 0.40 
52 V 1.092 -0.194 1.051 1.183 0.308 0.40 
53 I 1.038 -0.177 0.947 1.186 0.297 0.65 
54 Y 0.976 -0.182 0.993 1.083 0.465 0.85 T 
55 Q 0.923 -0.235 0.883 1.046 0.299 1.10 T 
56 G 0.880 -0.286 0.856 1.011 0.376 1.10 T 
57 K 0.852 -0.358 0.820 0.983 0.685 1.10 T 
58 P 0.844 -0.432 0.870 0.993 0.346 1.10 ST 
59 Y 0.849 -0.501 0.807 1.051 0.291 0.85 ST 
60 Y 0.862 -0.588 0.869 1.083 0.355 0.85 ST 
61 F 0.879 -0.643 0.773 1.104 0.383 0.65 S 
62 T 0.890 -0.718 0.874 1.123 0.384 0.65 S 
63 W 0.896 -0.739 0.956 1.073 0.292 0.65 S 
64 G 0.889 -0.750 1.001 0.997 0.333 0.90 S 
65 K 0.877 -0.751 0.987 1.016 0.366 0.90 
66 A 0.861 -0.751 1.053 0.971 0.241 0.65 
67 D 0.839 -0.772 1.040 0.917 0.307 0.65 
68 I 0.814 -0.768 1.089 0.894 0.401 0.65 
69 A 0.795 -0.775 1.087 0.939 0.388 0.85 
70 N 0.781 -0.792 0.977 0.901 0.405 1.10 
71 N 0.780 -0.806 0.959 1.011 0.295 1.10 
72 H 0.780 -0.801 0.939 0.977 0.636 1.10 T 
73 P 0.784 -0.748 0.936 0.963 0.313 1.10 ST 
74 V 0.801 -0.706 0.989 0.969 0.305 1.10 ST 
75 T 0.831 -0.674 0.979 1.033 0.300 1.10 ST 
76 Q 0.867 -0.626 0.990 1.024 0.307 0.50 S 
77 Q 0.906 -0.595 1.069 1.121 0.283 0.00 S 
78 T 0.935 -0.545 1.144 1.016 0.240 0.65 S 
79 L 0.967 -0.511 1.211 0.989 0.249 0.65 S 
80 F 0.998 -0.495 1.110 1.006 0.307 0.65 S 
81 E 1.019 -0.480 1.046 1.027 0.377 0.65 S 
82 L 1.026 -0.459 1.057 1.067 0.324 0.40 
83 G 1.021 -0.402 0.989 1.057 0.373 0.65 
84 S 1.009 -0.364 1.011 0.979 0.388 0.90 
85 V 1.005 -0.340 0.924 1.044 0.352 0.90 
86 S 1.001 -0.317 0.891 1.087 0.365 0.65 
87 K 0.994 -0.267 0.940 1.064 0.319 0.65 
88 T 0.993 -0.241 0.903 1.060 0.470 0.65 T 
89 F 1.000 -0.239 0.903 1.060 0.385 0.65 T 
90 N 1.016 -0.266 0.971 1.070 0.342 0.65 T 
91 G 1.033 -0.295 0.876 1.091 0.338 0.65 T 
92 V 1.041 -0.320 0.837 1.050 0.429 0.65 
93 L 1.039 -0.331 0.833 0.964 0.417 0.90 
94 G 1.041 -0.376 0.889 0.984 0.424 0.90 
95 G 1.033 -0.421 0.947 1.060 0.303 0.65 
96 D 1.016 -0.418 1.001 0.976 0.294 0.90 
97 A 0.988 -0.436 0.953 0.971 0.214 0.90 
98 I 0.957 -0.441 0.953 0.971 0.370 0.90 
99 A 0.925 -0.487 1.079 0.947 0.420 0.65 
100 R 0.900 -0.505 1.069 1.051 0.288 0.40 
101 G 0.870 -0.557 1.060 1.033 0.270 0.65 
102 E 0.844 -0.610 1.107 0.971 0.232 0.65 
103 I 0.822 -0.648 1.040 0.979 0.300 0.65 
104 K 0.805 -0.689 1.051 0.940 0.286 0.85 
105 L 0.792 -0.760 1.046 0.900 0.447 0.85 T 
106 S 0.785 -0.792 0.970 1.006 0.317 1.10 T 
107 D 0.776 -0.795 0.950 0.971 0.643 1.10 T 
108 P 0.769 -0.790 0.950 0.971 0.310 1.10 T 
109 V 0.765 -0.815 0.867 1.004 0.367 1.10 T 
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110 T 0.765 -0.812 0.891 1.031 0.482 1.10 T 
111 K 0.765 -0.797 0.817 1.020 0.252 1.10 T 
112 Y 0.765 -0.835 0.949 1.036 0.193 1.10 T 
113 W 0.765 -0.844 1.004 0.969 0.615 1.10 T 
114 P 0.767 -0.866 1.004 0.969 0.277 1.10 T 
115 E 0.769 -0.883 0.909 0.990 0.298 1.10 T 
116 L 0.765 -0.904 0.981 0.921 0.454 1.10 T 
117 T 0.760 -0.873 1.021 0.873 0.341 0.90 T 
118 G 0.761 -0.842 1.089 0.944 0.421 0.65 H T 
119 K 0.767 -0.821 1.064 0.951 0.315 0.65 HST 
120 Q 0.779 -0.808 0.959 0.937 0.276 0.90 HS 
121 W 0.801 -0.734 0.979 0.971 0.421 0.90 HS 
122 Q 0.829 -0.678 1.036 0.981 0.257 0.65 HS 
123 G 0.873 -0.660 1.046 1.017 0.305 0.65 HS 
124 I 0.924 -0.622 1.050 1.049 0.255 0.65 S 
125 R 0.970 -0.566 1.083 1.040 0.185 0.25 S 
126 L 1.018 -0.497 1.087 1.071 0.249 0.00 S 
127 L 1.059 -0.438 1.191 1.069 0.202 0.40 S 
128 H 1.091 -0.353 1.171 1.034 0.279 0.65 S 
129 L 1.116 -0.264 1.137 1.071 0.327 0.40 S 
130 A 1.129 -0.205 1.070 1.099 0.361 0.60 S 
131 T 1.133 -0.140 1.069 1.081 0.274 0.60 S 
132 Y 1.134 -0.107 0.974 1.059 0.377 0.85 S 
133 T 1.125 -0.120 0.869 1.044 0.504 1.10 ST 
134 A 1.111 -0.148 0.870 1.061 0.405 0.85 ST 
135 G 1.087 -0.180 0.826 0.980 0.291 1.10 ST 
136 G 1.057 -0.215 0.909 0.947 0.231 1.10 T 
137 L 1.016 -0.311 0.971 0.889 0.586 1.10 
138 P 0.966 -0.424 0.926 0.967 0.220 1.10 S 
139 L 0.904 -0.502 0.920 0.927 0.240 1.10 S 
140 Q 0.835 -0.579 0.989 0.899 0.223 1.10 S 
141 I 0.768 -0.652 0.951 0.856 0.694 1.10 ST 
142 P 0.715 -0.689 1.007 0.977 0.444 1.10 ST 
143 D 0.670 -0.732 0.959 0.973 0.368 1.10 T 
144 D 0.644 -0.739 0.926 0.961 0.375 1.10 T 
145 V 0.640 -0.760 0.963 0.864 0.442 0.90 T 
146 R 0.670 -0.781 1.073 0.901 0.310 0.65 T 
147 D 0.722 -0.838 1.109 0.927 0.355 0.65 T 
148 K 0.785 -0.904 1.146 0.970 0.236 0.65 ST 
149 A 0.844 -0.935 1.201 0.903 0.242 0.65 S 
150 A 0.899 -0.957 1.239 0.916 0.175 0.65 S 
151 L 0.942 -0.994 1.243 1.001 0.244 0.65 S 
152 L 0.960 -1.012 1.170 1.070 0.298 0.60 S 
153 H 0.946 -0.976 1.167 1.056 0.393 0.60 S 
154 F 0.910 -0.908 1.111 1.036 0.252 0.85 S 
155 Y 0.862 -0.847 1.067 1.053 0.538 0.60 ST 
156 Q 0.809 -0.806 1.063 1.021 0.319 0.85 ST 
157 N 0.762 -0.775 0.963 0.959 0.279 1.10 ST 
158 W 0.721 -0.800 0.991 0.884 0.307 1.10 ST 
159 Q 0.698 -0.818 1.030 0.869 0.669 1.10 ST 
160 P 0.694 -0.871 0.967 0.927 0.343 1.10 ST 
161 Q 0.702 -0.916 0.913 0.910 0.220 1.10 ST 
162 W 0.720 -0.963 0.851 0.879 0.371 1.10 ST 
163 T 0.743 -0.953 0.854 0.893 0.725 1.10 ST 
164 P 0.762 -0.900 0.956 0.911 0.317 1.10 ST 
165 G 0.781 -0.847 0.911 0.939 0.335 1.10 T 
166 A 0.802 -0.779 0.956 0.921 0.344 1.10 T 
167 K 0.820 -0.693 0.940 0.927 0.322 0.90 
168 R 0.841 -0.591 1.050 0.964 0.267 0.65 
169 L 0.863 -0.507 1.099 0.941 0.252 0.65 
170 Y 0.891 -0.422 1.031 0.949 0.455 0.65 T 
171 A 0.933 -0.362 0.973 0.974 0.374 0.90 T 
172 N 0.983 -0.308 0.974 1.040 0.481 0.90 T 
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173 S 1.032 -0.241 0.869 1.026 0.424 0.90 T 
174 S 1.086 -0.190 0.951 0.993 0.414 0.90 T 
175 I 1.136 -0.153 0.920 1.053 0.229 0.65 T 
176 G 1.180 -0.120 0.871 1.076 0.344 0.65 H 
177 L 1.211 -0.094 0.939 1.069 0.350 0.65 H 
178 F 1.225 -0.045 1.007 1.079 0.249 0.65 H 
179 G 1.221 -0.035 1.053 1.000 0.272 0.65 H 
180 A 1.203 -0.025 1.103 1.081 0.173 0.40 H 
181 L 1.165 -0.040 1.093 1.046 0.258 0.85 H 
182 A 1.119 -0.084 1.014 0.949 0.248 1.10 H 
183 V 1.071 -0.131 1.051 0.953 0.317 0.85 H 
184 K 1.024 -0.203 0.947 0.956 0.723 1.10 H T 
185 P 0.981 -0.278 0.971 0.949 0.486 1.10 H T 
186 S 0.945 -0.381 0.904 0.956 0.325 1.10 T 
187 G 0.914 -0.484 0.877 0.921 0.434 1.10 T 
188 M 0.890 -0.555 0.907 0.919 0.385 0.90 T 
189 S 0.872 -0.624 1.039 0.934 0.326 0.65 T 
190 Y 0.861 -0.677 1.106 0.927 0.277 0.65 T 
191 E 0.854 -0.727 1.236 0.934 0.206 0.65 
192 E 0.843 -0.739 1.144 0.969 0.225 0.65 
193 A 0.832 -0.748 1.164 0.974 0.292 0.65 
194 M 0.825 -0.757 1.199 0.937 0.360 0.65 
195 T 0.827 -0.760 1.123 1.043 0.344 0.65 
196 R 0.833 -0.795 1.103 1.081 0.272 0.40 
197 R 0.832 -0.806 1.100 1.067 0.252 0.60 
198 V 0.834 -0.807 0.964 1.020 0.192 1.10 
199 L 0.846 -0.769 1.031 0.993 0.263 0.85 
200 Q 0.865 -0.738 1.070 0.961 0.596 0.85 
201 P 0.892 -0.702 1.119 0.966 0.269 0.85 
202 L 0.916 -0.624 1.173 0.881 0.270 0.85 
203 K 0.938 -0.560 1.161 0.890 0.169 0.85 S 
204 L 0.967 -0.541 1.099 0.949 0.309 0.65 S 
205 A 0.991 -0.562 1.166 1.020 0.339 0.65 S 
206 H 1.005 -0.580 1.119 1.081 0.368 0.40 S 
207 T 1.005 -0.633 1.061 1.144 0.191 0.40 S 
208 W 0.983 -0.740 1.006 1.211 0.229 0.85 S 
209 I 0.939 -0.830 0.896 1.174 0.245 0.85 S 
210 T 0.880 -0.896 0.903 1.134 0.266 0.85 S 
211 V 0.808 -0.941 0.913 1.070 0.581 0.85 S 
212 P 0.732 -0.962 0.977 1.014 0.455 1.10 ST 
213 Q 0.660 -0.960 1.020 0.921 0.332 1.10 T 
214 N 0.599 -0.946 1.077 0.859 0.353 0.85 T 
215 E 0.558 -0.996 1.096 0.749 0.307 0.65 T 
216 Q 0.545 -1.039 1.124 0.836 0.493 0.65 T 
217 K 0.557 -1.109 1.127 0.850 0.337 0.65 T 
218 D 0.583 -1.203 1.140 0.904 0.414 0.65 T 
219 Y 0.615 -1.268 1.014 0.929 0.374 0.90 T 
220 A 0.647 -1.315 0.936 0.993 0.388 0.90 
221 W 0.672 -1.294 0.897 1.024 0.361 0.90 
222 G 0.692 -1.258 0.954 1.029 0.330 0.90 
223 Y 0.703 -1.157 0.931 0.981 0.417 0.90 T 
224 R 0.703 -1.030 0.923 0.963 0.415 1.10 T 
225 E 0.706 -0.944 0.856 0.891 0.281 1.10 T 
226 G 0.715 -0.852 0.906 0.973 0.304 1.10 T 
227 K 0.732 -0.808 0.977 0.949 0.526 1.10 
228 P 0.757 -0.781 0.970 1.020 0.296 1.10 
229 V 0.783 -0.802 0.881 1.049 0.241 1.10 
230 H 0.805 -0.817 0.876 1.009 0.381 1.10 
231 V 0.829 -0.795 0.780 1.030 0.387 1.55 
232 S 0.844 -0.778 0.887 1.053 0.799 0.85 T 
233 P 0.853 -0.706 0.943 0.986 0.294 1.10 T 
234 G 0.855 -0.663 0.917 0.934 0.317 1.10 T 
235 Q 0.854 -0.607 0.971 0.850 0.336 1.10 T 
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236 L 0.852 -0.560 1.060 0.821 0.270 0.65 
237 D 0.857 -0.535 1.170 0.859 0.358 0.65 
238 A 0.863 -0.499 1.193 0.906 0.280 0.65 
239 E 0.876 -0.520 1.091 0.923 0.398 0.65 
240 A 0.888 -0.516 1.036 0.990 0.368 0.65 
241 Y 0.900 -0.481 1.063 0.997 0.288 0.65 
242 G 0.915 -0.502 0.996 1.004 0.328 0.90 
243 V 0.932 -0.509 0.907 1.033 0.408 0.90 
244 K 0.945 -0.522 0.853 1.117 0.372 0.65 
245 S 0.957 -0.510 0.889 1.146 0.341 0.65 
246 S 0.959 -0.497 0.957 1.117 0.262 0.65 
247 V 0.963 -0.523 1.037 1.043 0.330 0.65 
248 I 0.967 -0.514 1.046 1.061 0.225 0.40 
249 D 0.961 -0.551 1.066 1.067 0.349 0.40 
250 M 0.951 -0.559 1.090 1.094 0.410 0.40 
251 A 0.938 -0.573 1.090 1.094 0.283 0.40 
252 R 0.922 -0.609 1.133 1.001 0.207 0.65 
253 W 0.912 -0.629 1.169 1.027 0.220 0.65 
254 V 0.898 -0.677 1.087 0.997 0.286 0.65 
255 Q 0.886 -0.695 1.113 1.007 0.396 0.65 
256 A 0.877 -0.779 1.124 0.969 0.238 0.65 
257 N 0.867 -0.868 1.167 0.934 0.480 0.65 T 
258 M 0.855 -0.899 1.154 0.857 0.319 0.65 T 
259 D 0.844 -0.941 1.147 0.897 0.402 0.65 T 
260 A 0.828 -0.979 1.093 0.981 0.345 0.65 T 
261 S 0.807 -0.996 1.146 0.987 0.291 0.65 
262 H 0.780 -0.973 1.141 0.956 0.289 0.65 
263 V 0.758 -0.923 1.169 0.963 0.332 0.65 
264 Q 0.745 -0.902 1.103 1.007 0.285 0.25 
265 E 0.744 -0.846 1.171 1.017 0.306 0.65 
266 K 0.751 -0.784 1.179 0.977 0.297 0.65 
267 T 0.769 -0.743 1.230 0.879 0.246 0.65 
268 L 0.805 -0.715 1.129 0.896 0.348 0.65 
269 Q 0.854 -0.722 1.061 0.996 0.418 0.65 
270 Q 0.902 -0.725 1.070 1.014 0.230 0.65 
271 G 0.942 -0.757 1.137 0.987 0.241 0.65 S 
272 I 0.965 -0.727 1.136 0.970 0.213 0.65 S 
273 A 0.976 -0.694 1.136 0.970 0.218 0.65 S 
274 L 0.973 -0.685 1.071 0.991 0.280 0.85 S 
275 A 0.950 -0.645 1.129 1.001 0.368 0.85 S 
276 Q 0.916 -0.600 1.093 0.973 0.437 0.85 ST 
277 S 0.879 -0.572 1.050 1.007 0.507 0.85 ST 
278 R 0.843 -0.593 1.001 1.003 0.284 1.10 T 
279 Y 0.819 -0.614 0.956 1.081 0.250 0.85 T 
280 W 0.807 -0.609 0.854 1.099 0.348 0.85 T 
281 R 0.801 -0.636 0.886 1.066 0.375 0.65 
282 I 0.813 -0.685 0.959 1.063 0.362 0.65 
283 G 0.828 -0.710 0.959 1.063 0.351 0.65 
284 D 0.845 -0.692 0.999 1.014 0.441 0.90 T 
285 M 0.872 -0.694 0.941 1.004 0.322 0.90 T 
286 Y 0.897 -0.691 0.989 0.943 0.440 0.90 T 
287 Q 0.917 -0.653 0.989 0.943 0.347 0.90 T 
288 G 0.935 -0.611 0.981 1.003 0.484 0.90 T 
289 L 0.944 -0.606 0.977 0.971 0.274 0.90 T 
290 G 0.953 -0.608 1.084 0.931 0.247 0.65 
291 W 0.959 -0.619 1.089 0.963 0.221 0.65 
292 E 0.950 -0.628 1.137 0.940 0.265 0.65 
293 M 0.934 -0.631 1.093 0.957 0.451 0.85 
294 L 0.916 -0.622 1.087 0.917 0.276 0.85 
295 N 0.902 -0.608 1.131 0.900 0.278 0.85 
296 W 0.887 -0.620 1.101 0.903 0.599 0.85 T 
297 P 0.873 -0.599 1.076 0.893 0.257 0.85 T 
298 L 0.861 -0.580 1.039 0.850 0.292 0.85 T 
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299 K 0.861 -0.592 1.027 0.877 0.416 1.10 T 
300 A 0.868 -0.650 1.024 0.921 0.351 0.90 
301 D 0.873 -0.653 1.089 1.037 0.355 0.65 
302 S 0.871 -0.644 1.031 1.000 0.258 0.65 
303 I 0.871 -0.631 0.936 1.021 0.420 1.10 
304 I 0.869 -0.624 0.869 1.029 0.422 1.10 
305 N 0.867 -0.580 0.869 1.029 0.452 1.10 T 
306 G 0.866 -0.495 0.869 1.029 0.526 1.10 T 
307 S 0.869 -0.419 0.906 0.931 0.450 1.10 T 
308 D 0.887 -0.350 0.897 0.937 0.411 1.10 T 
309 S 0.921 -0.295 0.953 0.957 0.319 1.10 T 
310 K 0.964 -0.273 1.059 0.971 0.208 0.65 T 
311 V 1.012 -0.255 1.126 0.964 0.232 0.65 
312 A 1.061 -0.264 1.161 0.990 0.178 0.25 
313 L 1.102 -0.296 1.230 1.000 0.242 0.85 
314 A 1.129 -0.313 1.129 0.981 0.240 0.85 
315 A 1.136 -0.323 1.183 0.897 0.177 0.85 
316 L 1.121 -0.270 1.129 0.981 0.540 0.85 
317 P 1.086 -0.251 1.149 0.943 0.268 0.85 
318 A 1.042 -0.205 1.094 1.027 0.238 0.85 
319 V 0.991 -0.193 1.039 1.007 0.239 0.85 
320 E 0.940 -0.200 0.927 0.953 0.363 1.10 
321 V 0.900 -0.215 0.927 0.953 0.247 1.10 
322 N 0.873 -0.272 0.927 0.953 0.644 1.10 T 
323 P 0.858 -0.313 0.871 0.831 0.596 1.10 T 
324 P 0.863 -0.383 0.850 0.853 0.270 1.10 T 
325 A 0.874 -0.455 0.850 0.853 0.539 1.10 T 
326 P 0.889 -0.502 0.897 0.854 0.299 1.10 
327 A 0.908 -0.551 1.007 0.891 0.238 1.10 
328 V 0.925 -0.565 1.050 0.936 0.318 0.85 
329 K 0.935 -0.587 1.007 0.970 0.423 0.90 
330 A 0.941 -0.578 1.063 1.091 0.316 0.40 
331 S 0.936 -0.530 1.053 1.117 0.213 0.40 
332 W 0.927 -0.499 1.099 1.014 0.313 0.65 
333 V 0.927 -0.462 1.041 1.077 0.260 0.40 
334 H 0.929 -0.454 0.937 1.080 0.472 0.65 T 
335 K 0.936 -0.422 0.937 1.080 0.459 0.85 T 
336 T 0.950 -0.392 0.914 1.090 0.375 0.85 T 
337 G 0.970 -0.357 0.864 1.009 0.458 1.10 T 
338 S 1.000 -0.317 0.770 0.986 0.570 1.10 T 
339 T 1.038 -0.276 0.747 1.064 0.426 0.85 T 
340 G 1.070 -0.209 0.709 1.023 0.404 1.10 T 
341 G 1.099 -0.162 0.746 1.027 0.439 1.10 T 
342 F 1.121 -0.151 0.731 1.070 0.394 0.65 
343 G 1.135 -0.167 0.743 1.110 0.408 0.65 
344 S 1.138 -0.188 0.847 1.107 0.269 0.65 S 
345 Y 1.126 -0.206 0.920 1.164 0.230 0.65 S 
346 V 1.097 -0.235 0.897 1.189 0.256 0.85 S 
347 A 1.057 -0.263 0.891 1.149 0.195 0.85 S 
348 F 1.011 -0.264 0.980 1.120 0.205 0.85 S 
349 V 0.966 -0.237 1.053 1.051 0.625 0.60 ST 
350 P 0.931 -0.215 1.051 0.947 0.325 0.85 ST 
351 E 0.915 -0.211 1.053 0.964 0.432 0.85 T 
352 K 0.915 -0.255 0.980 0.907 0.326 1.10 T 
353 N 0.932 -0.309 0.989 0.901 0.432 0.90 
354 L 0.964 -0.368 1.044 1.023 0.212 0.65 
355 G 1.004 -0.444 1.049 1.054 0.217 0.40 
356 I 1.038 -0.540 1.059 1.090 0.175 0.40 
357 V 1.055 -0.598 1.114 1.110 0.238 0.40 
358 M 1.043 -0.580 1.057 1.073 0.219 0.60 
359 L 1.011 -0.565 1.153 1.051 0.423 0.60 
360 A 0.964 -0.541 1.131 0.980 0.321 0.85 
361 N 0.906 -0.531 1.104 0.946 0.526 0.85 T 
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362 K 0.842 -0.513 0.969 0.899 0.376 1.10 T 
363 S 0.781 -0.520 0.911 0.861 0.310 1.10 T 
364 Y 0.739 -0.577 0.801 0.824 0.732 1.10 T 
365 P 0.723 -0.661 0.803 0.929 0.272 1.10 T 
366 N 0.721 -0.738 0.764 0.960 0.663 1.10 T 
367 P 0.734 -0.761 0.777 1.037 0.302 1.10 T 
368 V 0.757 -0.771 0.880 0.966 0.258 1.10 T 
369 R 0.794 -0.807 0.990 1.003 0.253 1.10 T 
370 V 0.832 -0.821 1.046 1.023 0.215 0.25 
371 E 0.863 -0.814 1.113 1.094 0.334 0.00 S 
372 A 0.880 -0.801 1.120 1.023 0.285 0.25 S 
373 A 0.895 -0.600 1.121 1.089 0.228 0.00 S 
374 W 0.895 -0.600 1.177 1.021 0.266 0.25 S 
375 R 0.887 -0.600 1.177 1.021 0.204 0.25 S 
376 I 0.868 -0.600 1.169 1.003 0.240 0.25 S 
377 L 0.846 -0.600 1.170 1.020 0.263 0.25 S 
378 E 0.824 -0.600 1.210 0.971 0.305 0.25 S 
379 K 0.816 -0.600 1.073 0.830 0.117 0.25 
380 L 0.797 -0.600 1.048 0.668 0.000 0.25 
381 Q 0.791 -0.600 0.857 0.607 0.000 0.50 
382 * 0.830 -0.600 0.000 0.000 0.000 1.40 
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Key: 
Argos = Argos transmembrane 
vH trns = von Heijne transmembrane 
CFhlx = Chou-Fasman Alpha Helix 
CFsht = Chou-Fasman Beta Sheet 
CFturn = Chou-Fasman Turn 
CFval = Chou-Fasman Structure Value 
CFtype = Chou-Fasman Probable Type 
Pos. AA Argos vH trns CFhlx CFsht CFturn CFval CFtype 
1 M 1.420 -0.600 1.470 0.970 0.317 0.65 H 
2 M 1.168 -0.600 1.390 0.903 0.361 0.65 H 
3 K 1.107 -0.600 1.244 0.886 0.365 0.65 H 
4 K 1.107 -0.600 1.233 0.884 0.358 0.65 H 
5 S 1.076 -0.600 1.181 0.851 0.390 0.65 H 
6 L 1.103 -0.600 1.156 0.841 0.289 0.65 H 
7 C 1.146 -0.600 1.166 0.877 0.307 0.65 H 
8 C 1.190 -0.600 1.176 0.913 0.331 0.65 H 
9 A 1.234 -0.600 1.244 0.923 0.191 0.25 H 
10 L 1.267 -0.600 1.177 0.950 0.201 0.65 H 
11 L 1.286 0.221 1.203 0.973 0.209 0.65 H 
12 L 1.296 0.286 1.161 1.003 0.310 0.65 H 
13 T 1.299 0.303 1.130 1.063 0.352 0.40 H 
14 A 1.288 0.303 1.061 1.053 0.370 0.40 H 
15 S 1.272 0.240 0.994 1.080 0.365 0.65 H 
16 F 1.254 0.117 0.961 1.123 0.328 0.65 H 
17 S 1.231 -0.036 1.027 1.079 0.351 0.65 H 
18 T 1.198 -0.181 1.027 1.079 0.220 0.65 H 
19 F 1.155 -0.272 1.094 1.071 0.228 0.40 H 
20 A 1.099 -0.370 1.117 0.993 0.266 0.65 H 
21 A 1.039 -0.429 1.119 1.030 0.287 0.25 H 
22 A 0.974 -0.460 1.206 0.964 0.304 0.25 H 
23 K 0.912 -0.484 1.234 0.890 0.338 0.25 H 
24 T 0.859 -0.540 1.231 0.876 0.281 0.25 H 
25 E 0.822 -0.605 1.186 0.954 0.247 0.65 H 
26 Q 0.799 -0.636 1.186 0.954 0.243 0.65 H 
27 Q 0.793 -0.682 1.159 0.947 0.224 0.65 H 
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28 I 0.800 -0.738 1.179 0.981 0.354 0.65 H 
29 A 0.818 -0.737 1.103 1.087 0.236 0.40 H 
30 D 0.836 -0.706 1.050 1.081 0.298 0.40 H 
31 I 0.856 -0.664 1.006 1.109 0.367 0.65 H 
32 V 0.874 -0.635 0.986 1.074 0.323 0.65 H 
33 N 0.892 -0.602 0.940 1.153 0.388 0.65 H 
34 R 0.905 -0.570 0.910 1.223 0.270 0.85 
35 T 0.910 -0.567 0.846 1.107 0.253 0.85 
36 I 0.913 -0.548 0.901 1.040 0.255 1.10 
37 T 0.917 -0.544 0.983 1.070 0.568 0.85 
38 P 0.912 -0.539 1.027 1.043 0.239 1.10 
39 L 0.902 -0.511 1.114 0.977 0.244 0.85 
40 M 0.892 -0.439 1.157 0.884 0.341 0.85 
41 Q 0.894 -0.371 1.223 0.840 0.229 0.65 
42 E 0.907 -0.325 1.287 0.956 0.245 0.85 
43 Q 0.923 -0.259 1.176 0.901 0.231 0.85 
44 A 0.952 -0.187 1.046 0.894 0.280 0.85 
45 I 0.998 -0.164 1.074 0.919 0.679 0.85 T 
46 P 1.051 -0.176 1.053 0.940 0.259 0.85 T 
47 G 1.101 -0.204 1.001 1.039 0.272 1.10 T 
48 M 1.137 -0.210 1.001 1.039 0.228 1.10 T 
49 A 1.155 -0.211 0.993 1.044 0.196 0.50 
50 V 1.159 -0.219 1.057 1.160 0.220 0.00 
51 A 1.137 -0.208 1.080 1.207 0.246 0.40 
52 V 1.092 -0.194 1.051 1.183 0.308 0.40 
53 I 1.038 -0.177 0.947 1.186 0.297 0.65 
54 Y 0.976 -0.182 0.993 1.083 0.465 0.85 T 
55 Q 0.923 -0.235 0.883 1.046 0.299 1.10 T 
56 G 0.880 -0.286 0.856 1.011 0.376 1.10 T 
57 K 0.852 -0.358 0.820 0.983 0.685 1.10 T 
58 P 0.844 -0.432 0.870 0.993 0.346 1.10 ST 
59 Y 0.849 -0.501 0.807 1.051 0.291 0.85 ST 
60 Y 0.862 -0.588 0.869 1.083 0.355 0.85 ST 
61 F 0.879 -0.643 0.773 1.104 0.383 0.65 S 
62 T 0.890 -0.718 0.874 1.123 0.384 0.65 S 
63 W 0.896 -0.739 0.956 1.073 0.292 0.65 S 
64 G 0.889 -0.750 1.001 0.997 0.333 0.90 S 
65 K 0.877 -0.751 0.987 1.016 0.366 0.90 
66 A 0.861 -0.751 1.053 0.971 0.241 0.65 
67 D 0.839 -0.772 1.040 0.917 0.307 0.65 
68 I 0.814 -0.768 1.089 0.894 0.401 0.65 
69 A 0.795 -0.775 1.087 0.939 0.388 0.85 
70 N 0.781 -0.792 0.977 0.901 0.405 1.10 
71 N 0.780 -0.806 0.959 1.011 0.295 1.10 
72 H 0.780 -0.801 0.939 0.977 0.636 1.10 T 
73 P 0.784 -0.748 0.936 0.963 0.313 1.10 ST 
74 V 0.801 -0.706 0.989 0.969 0.305 1.10 ST 
75 T 0.831 -0.674 0.979 1.033 0.300 1.10 ST 
76 Q 0.867 -0.626 0.990 1.024 0.307 0.50 S 
77 Q 0.906 -0.595 1.069 1.121 0.283 0.00 S 
78 T 0.935 -0.545 1.144 1.016 0.240 0.65 S 
79 L 0.967 -0.511 1.211 0.989 0.249 0.65 S 
80 F 0.998 -0.495 1.110 1.006 0.307 0.65 S 
81 E 1.019 -0.480 1.046 1.027 0.377 0.65 S 
82 L 1.026 -0.459 1.057 1.067 0.324 0.40 
83 G 1.021 -0.402 0.989 1.057 0.373 0.65 
84 S 1.009 -0.364 1.011 0.979 0.388 0.90 
85 V 1.005 -0.340 0.924 1.044 0.352 0.90 
86 S 1.001 -0.317 0.891 1.087 0.365 0.65 
87 K 0.994 -0.267 0.940 1.064 0.319 0.65 
88 T 0.993 -0.241 0.903 1.060 0.470 0.65 T 
89 F 1.000 -0.239 0.903 1.060 0.385 0.65 T 
90 N 1.016 -0.266 0.971 1.070 0.342 0.65 T 
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91 G 1.033 -0.295 0.876 1.091 0.338 0.65 T 
92 V 1.041 -0.320 0.837 1.050 0.429 0.65 
93 L 1.039 -0.331 0.833 0.964 0.417 0.90 
94 G 1.041 -0.376 0.889 0.984 0.424 0.90 
95 G 1.033 -0.421 0.947 1.060 0.303 0.65 
96 D 1.016 -0.418 1.001 0.976 0.294 0.90 
97 A 0.988 -0.436 0.953 0.971 0.214 0.90 
98 I 0.957 -0.441 0.953 0.971 0.370 0.90 
99 A 0.925 -0.487 1.079 0.947 0.420 0.65 
100 R 0.900 -0.505 1.069 1.051 0.288 0.40 
101 G 0.870 -0.557 1.060 1.033 0.270 0.65 
102 E 0.844 -0.610 1.107 0.971 0.232 0.65 
103 I 0.822 -0.648 1.040 0.979 0.300 0.65 
104 K 0.805 -0.689 1.051 0.940 0.286 0.85 
105 L 0.792 -0.760 1.046 0.900 0.447 0.85 T 
106 S 0.785 -0.792 0.970 1.006 0.317 1.10 T 
107 D 0.776 -0.795 0.950 0.971 0.643 1.10 T 
108 P 0.769 -0.790 0.950 0.971 0.310 1.10 T 
109 V 0.765 -0.815 0.867 1.004 0.367 1.10 T 
110 T 0.765 -0.812 0.891 1.031 0.482 1.10 T 
111 K 0.765 -0.797 0.817 1.020 0.252 1.10 T 
112 Y 0.765 -0.835 0.949 1.036 0.193 1.10 T 
113 W 0.765 -0.844 1.004 0.969 0.615 1.10 T 
114 P 0.767 -0.866 1.004 0.969 0.277 1.10 T 
115 E 0.769 -0.883 0.909 0.990 0.298 1.10 T 
116 L 0.765 -0.904 0.981 0.921 0.454 1.10 T 
117 T 0.760 -0.873 1.021 0.873 0.341 0.90 T 
118 G 0.761 -0.842 1.089 0.944 0.421 0.65 H T 
119 K 0.767 -0.821 1.064 0.951 0.315 0.65 HST 
120 Q 0.779 -0.808 0.959 0.937 0.276 0.90 HS 
121 W 0.801 -0.734 0.979 0.971 0.421 0.90 HS 
122 Q 0.829 -0.678 1.036 0.981 0.257 0.65 HS 
123 G 0.873 -0.660 1.046 1.017 0.305 0.65 HS 
124 I 0.924 -0.622 1.050 1.049 0.255 0.65 S 
125 R 0.970 -0.566 1.083 1.040 0.185 0.25 S 
126 L 1.018 -0.497 1.087 1.071 0.249 0.00 S 
127 L 1.059 -0.438 1.191 1.069 0.202 0.40 S 
128 H 1.091 -0.353 1.171 1.034 0.279 0.65 S 
129 L 1.116 -0.264 1.137 1.071 0.327 0.40 S 
130 A 1.129 -0.205 1.070 1.099 0.361 0.60 S 
131 T 1.133 -0.140 1.069 1.081 0.274 0.60 S 
132 Y 1.134 -0.107 0.974 1.059 0.377 0.85 S 
133 T 1.125 -0.120 0.869 1.044 0.504 1.10 ST 
134 A 1.111 -0.148 0.870 1.061 0.405 0.85 ST 
135 G 1.087 -0.180 0.826 0.980 0.291 1.10 ST 
136 G 1.057 -0.215 0.909 0.947 0.231 1.10 T 
137 L 1.016 -0.311 0.971 0.889 0.586 1.10 
138 P 0.966 -0.424 0.926 0.967 0.220 1.10 S 
139 L 0.904 -0.502 0.920 0.927 0.240 1.10 S 
140 Q 0.835 -0.579 0.989 0.899 0.223 1.10 S 
141 I 0.768 -0.652 0.951 0.856 0.694 1.10 ST 
142 P 0.715 -0.689 1.007 0.977 0.444 1.10 ST 
143 D 0.670 -0.732 0.959 0.973 0.368 1.10 T 
144 D 0.644 -0.739 0.926 0.961 0.375 1.10 T 
145 V 0.640 -0.760 0.963 0.864 0.442 0.90 T 
146 R 0.670 -0.781 1.073 0.901 0.310 0.65 T 
147 D 0.722 -0.838 1.109 0.927 0.355 0.65 T 
148 K 0.785 -0.904 1.146 0.970 0.236 0.65 ST 
149 A 0.844 -0.935 1.201 0.903 0.242 0.65 S 
150 A 0.899 -0.957 1.239 0.916 0.175 0.65 S 
151 L 0.942 -0.994 1.243 1.001 0.244 0.65 S 
152 L 0.960 -1.012 1.170 1.070 0.298 0.60 S 
153 H 0.946 -0.976 1.167 1.056 0.393 0.60 S 
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154 F 0.910 -0.908 1.111 1.036 0.252 0.85 S 
155 Y 0.862 -0.847 1.067 1.053 0.538 0.60 ST 
156 Q 0.809 -0.806 1.063 1.021 0.319 0.85 ST 
157 N 0.762 -0.775 0.963 0.959 0.279 1.10 ST 
158 W 0.721 -0.800 0.991 0.884 0.307 1.10 ST 
159 Q 0.698 -0.818 1.030 0.869 0.669 1.10 ST 
160 P 0.694 -0.871 0.967 0.927 0.343 1.10 ST 
161 Q 0.702 -0.916 0.913 0.910 0.220 1.10 ST 
162 W 0.720 -0.963 0.851 0.879 0.371 1.10 ST 
163 T 0.743 -0.953 0.854 0.893 0.725 1.10 ST 
164 P 0.762 -0.900 0.956 0.911 0.317 1.10 ST 
165 G 0.781 -0.847 0.911 0.939 0.335 1.10 T 
166 A 0.802 -0.779 0.956 0.921 0.344 1.10 T 
167 K 0.820 -0.693 0.940 0.927 0.322 0.90 
168 R 0.841 -0.591 1.050 0.964 0.267 0.65 
169 L 0.863 -0.507 1.099 0.941 0.252 0.65 
170 Y 0.891 -0.422 1.031 0.949 0.455 0.65 T 
171 A 0.933 -0.362 0.973 0.974 0.374 0.90 T 
172 N 0.983 -0.308 0.974 1.040 0.481 0.90 T 
173 S 1.032 -0.241 0.869 1.026 0.424 0.90 T 
174 S 1.086 -0.190 0.951 0.993 0.414 0.90 T 
175 I 1.136 -0.153 0.920 1.053 0.229 0.65 T 
176 G 1.180 -0.120 0.871 1.076 0.344 0.65 H 
177 L 1.211 -0.094 0.939 1.069 0.350 0.65 H 
178 F 1.225 -0.045 1.007 1.079 0.249 0.65 H 
179 G 1.221 -0.035 1.053 1.000 0.272 0.65 H 
180 A 1.203 -0.025 1.103 1.081 0.173 0.40 H 
181 L 1.165 -0.040 1.093 1.046 0.258 0.85 H 
182 A 1.119 -0.084 1.014 0.949 0.248 1.10 H 
183 V 1.071 -0.131 1.051 0.953 0.317 0.85 H 
184 K 1.024 -0.203 0.947 0.956 0.723 1.10 H T 
185 P 0.981 -0.278 0.971 0.949 0.486 1.10 H T 
186 S 0.945 -0.381 0.904 0.956 0.325 1.10 T 
187 G 0.914 -0.484 0.877 0.921 0.434 1.10 T 
188 M 0.890 -0.555 0.907 0.919 0.385 0.90 T 
189 S 0.872 -0.624 1.039 0.934 0.326 0.65 T 
190 Y 0.861 -0.677 1.106 0.927 0.277 0.65 T 
191 E 0.854 -0.727 1.236 0.934 0.206 0.65 
192 E 0.843 -0.739 1.144 0.969 0.225 0.65 
193 A 0.832 -0.748 1.164 0.974 0.292 0.65 
194 M 0.825 -0.757 1.199 0.937 0.360 0.65 
195 T 0.827 -0.760 1.123 1.043 0.344 0.65 
196 R 0.833 -0.795 1.103 1.081 0.272 0.40 
197 R 0.832 -0.806 1.100 1.067 0.252 0.60 
198 V 0.834 -0.807 0.964 1.020 0.192 1.10 
199 L 0.846 -0.769 1.031 0.993 0.263 0.85 
200 Q 0.865 -0.738 1.070 0.961 0.596 0.85 
201 P 0.892 -0.702 1.119 0.966 0.269 0.85 
202 L 0.916 -0.624 1.173 0.881 0.270 0.85 
203 K 0.938 -0.560 1.161 0.890 0.169 0.85 S 
204 L 0.967 -0.541 1.099 0.949 0.309 0.65 S 
205 A 0.991 -0.562 1.166 1.020 0.339 0.65 S 
206 H 1.005 -0.580 1.119 1.081 0.368 0.40 S 
207 T 1.005 -0.633 1.061 1.144 0.191 0.40 S 
208 W 0.983 -0.740 1.006 1.211 0.229 0.85 S 
209 I 0.939 -0.830 0.896 1.174 0.245 0.85 S 
210 T 0.880 -0.896 0.903 1.134 0.266 0.85 S 
211 V 0.808 -0.941 0.913 1.070 0.581 0.85 S 
212 P 0.732 -0.962 0.977 1.014 0.455 1.10 ST 
213 Q 0.660 -0.960 1.020 0.921 0.332 1.10 T 
214 N 0.599 -0.946 1.077 0.859 0.353 0.85 T 
215 E 0.558 -0.996 1.096 0.749 0.307 0.65 T 
216 Q 0.545 -1.039 1.124 0.836 0.493 0.65 T 
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217 K 0.557 -1.109 1.127 0.850 0.337 0.65 T 
218 D 0.583 -1.203 1.140 0.904 0.414 0.65 T 
219 Y 0.615 -1.268 1.014 0.929 0.374 0.90 T 
220 A 0.647 -1.315 0.936 0.993 0.388 0.90 
221 W 0.672 -1.294 0.897 1.024 0.361 0.90 
222 G 0.692 -1.258 0.954 1.029 0.330 0.90 
223 Y 0.703 -1.157 0.931 0.981 0.417 0.90 T 
224 R 0.703 -1.030 0.923 0.963 0.415 1.10 T 
225 E 0.706 -0.944 0.856 0.891 0.281 1.10 T 
226 G 0.715 -0.852 0.906 0.973 0.304 1.10 T 
227 K 0.732 -0.808 0.977 0.949 0.526 1.10 
228 P 0.757 -0.781 0.970 1.020 0.296 1.10 
229 V 0.783 -0.802 0.881 1.049 0.241 1.10 
230 H 0.805 -0.817 0.876 1.009 0.381 1.10 
231 V 0.829 -0.795 0.780 1.030 0.387 1.55 
232 S 0.844 -0.778 0.887 1.053 0.799 0.85 T 
233 P 0.853 -0.706 0.943 0.986 0.294 1.10 T 
234 G 0.855 -0.663 0.917 0.934 0.317 1.10 T 
235 Q 0.854 -0.607 0.971 0.850 0.336 1.10 T 
236 L 0.852 -0.560 1.060 0.821 0.270 0.65 
237 D 0.857 -0.535 1.170 0.859 0.358 0.65 
238 A 0.863 -0.499 1.193 0.906 0.280 0.65 
239 E 0.876 -0.520 1.091 0.923 0.398 0.65 
240 A 0.888 -0.516 1.036 0.990 0.368 0.65 
241 Y 0.900 -0.481 1.063 0.997 0.288 0.65 
242 G 0.915 -0.502 0.996 1.004 0.328 0.90 
243 V 0.932 -0.509 0.907 1.033 0.408 0.90 
244 K 0.945 -0.522 0.853 1.117 0.372 0.65 
245 S 0.957 -0.510 0.889 1.146 0.341 0.65 
246 S 0.959 -0.497 0.957 1.117 0.262 0.65 
247 V 0.963 -0.523 1.037 1.043 0.330 0.65 
248 I 0.967 -0.514 1.046 1.061 0.225 0.40 
249 D 0.961 -0.551 1.066 1.067 0.349 0.40 
250 M 0.951 -0.559 1.090 1.094 0.410 0.40 
251 A 0.938 -0.573 1.090 1.094 0.283 0.40 
252 R 0.922 -0.609 1.133 1.001 0.207 0.65 
253 W 0.912 -0.629 1.169 1.027 0.220 0.65 
254 V 0.898 -0.677 1.087 0.997 0.286 0.65 
255 Q 0.886 -0.695 1.113 1.007 0.396 0.65 
256 A 0.877 -0.779 1.124 0.969 0.238 0.65 
257 N 0.867 -0.868 1.167 0.934 0.480 0.65 T 
258 M 0.855 -0.899 1.154 0.857 0.319 0.65 T 
259 D 0.844 -0.941 1.147 0.897 0.402 0.65 T 
260 A 0.828 -0.979 1.093 0.981 0.345 0.65 T 
261 S 0.807 -0.996 1.146 0.987 0.291 0.65 
262 H 0.780 -0.973 1.141 0.956 0.289 0.65 
263 V 0.758 -0.923 1.169 0.963 0.332 0.65 
264 Q 0.745 -0.902 1.103 1.007 0.285 0.25 
265 E 0.744 -0.846 1.171 1.017 0.306 0.65 
266 K 0.751 -0.784 1.179 0.977 0.297 0.65 
267 T 0.769 -0.743 1.230 0.879 0.246 0.65 
268 L 0.805 -0.680 1.129 0.896 0.348 0.65 
269 Q 0.858 -0.652 1.061 0.996 0.418 0.65 
270 Q 0.914 -0.620 1.070 1.014 0.230 0.65 
271 G 0.965 -0.617 1.137 0.987 0.241 0.65 S 
272 I 1.004 -0.551 1.136 0.970 0.213 0.65 S 
273 A 1.033 -0.483 1.136 0.970 0.218 0.65 S 
274 L 1.054 -0.475 1.071 0.991 0.280 0.65 S 
275 A 1.058 -0.434 1.177 1.006 0.353 0.65 S 
276 Q 1.043 -0.389 1.141 0.977 0.374 0.65 S 
277 S 1.018 -0.361 1.099 1.011 0.426 0.65 S 
278 L 0.985 -0.383 1.050 1.007 0.275 0.65 S 
279 Y 0.957 -0.403 1.004 1.086 0.250 0.65 S 
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280 W 0.934 -0.398 0.903 1.103 0.348 0.65 S 
281 R 0.909 -0.425 0.934 1.070 0.375 0.65 S 
282 I 0.894 -0.474 0.959 1.063 0.362 0.65 S 
283 G 0.885 -0.499 0.959 1.063 0.351 0.65 S 
284 D 0.884 -0.516 0.999 1.014 0.441 0.90 T 
285 M 0.895 -0.553 0.941 1.004 0.322 0.90 T 
286 Y 0.908 -0.586 0.989 0.943 0.440 0.90 T 
287 Q 0.921 -0.583 0.989 0.943 0.347 0.90 T 
288 G 0.935 -0.576 0.981 1.003 0.484 0.90 T 
289 L 0.944 -0.606 0.977 0.971 0.274 0.90 T 
290 G 0.953 -0.608 1.084 0.931 0.247 0.65 
291 W 0.959 -0.619 1.089 0.963 0.221 0.65 
292 E 0.950 -0.628 1.137 0.940 0.265 0.65 
293 M 0.934 -0.631 1.093 0.957 0.451 0.85 
294 L 0.916 -0.622 1.087 0.917 0.276 0.85 
295 N 0.902 -0.608 1.131 0.900 0.278 0.85 
296 W 0.887 -0.620 1.101 0.903 0.599 0.85 T 
297 P 0.873 -0.599 1.076 0.893 0.257 0.85 T 
298 L 0.861 -0.580 1.039 0.850 0.292 0.85 T 
299 K 0.861 -0.592 1.027 0.877 0.416 1.10 T 
300 A 0.868 -0.650 1.024 0.921 0.351 0.90 
301 D 0.873 -0.653 1.089 1.037 0.355 0.65 
302 S 0.871 -0.644 1.031 1.000 0.258 0.65 
303 I 0.871 -0.631 0.936 1.021 0.420 1.10 
304 I 0.869 -0.619 0.869 1.029 0.422 1.10 
305 N 0.867 -0.571 0.869 1.029 0.452 1.10 T 
306 G 0.866 -0.481 0.869 1.029 0.526 1.10 T 
307 S 0.870 -0.400 0.906 0.931 0.450 1.10 T 
308 D 0.887 -0.326 0.897 0.937 0.411 1.10 T 
309 S 0.922 -0.267 0.953 0.957 0.319 1.10 T 
310 K 0.965 -0.244 1.059 0.971 0.208 0.65 T 
311 V 1.013 -0.227 1.071 1.049 0.227 0.65 
312 A 1.062 -0.236 1.107 1.074 0.169 0.00 
313 L 1.104 -0.268 1.176 1.084 0.214 0.60 
314 V 1.130 -0.284 1.074 1.066 0.242 0.60 
315 A 1.137 -0.294 1.129 0.981 0.177 0.85 
316 L 1.122 -0.242 1.074 1.066 0.540 0.60 
317 P 1.087 -0.223 1.094 1.027 0.268 0.85 
318 A 1.043 -0.176 1.094 1.027 0.238 0.85 
319 V 0.991 -0.164 1.039 1.007 0.239 0.85 
320 E 0.941 -0.176 0.927 0.953 0.363 1.10 
321 V 0.901 -0.196 0.927 0.953 0.247 1.10 
322 N 0.873 -0.258 0.927 0.953 0.644 1.10 T 
323 P 0.858 -0.303 0.871 0.831 0.596 1.10 T 
324 P 0.863 -0.379 0.850 0.853 0.270 1.10 T 
325 A 0.874 -0.455 0.850 0.853 0.539 1.10 T 
326 P 0.889 -0.502 0.897 0.854 0.299 1.10 
327 A 0.908 -0.551 1.007 0.891 0.238 1.10 
328 V 0.925 -0.565 1.050 0.936 0.318 0.85 
329 K 0.935 -0.587 1.007 0.970 0.423 0.90 
330 A 0.941 -0.578 1.063 1.091 0.316 0.40 
331 S 0.936 -0.530 1.053 1.117 0.213 0.40 
332 W 0.927 -0.499 1.099 1.014 0.313 0.65 
333 V 0.927 -0.462 1.041 1.077 0.260 0.40 
334 H 0.929 -0.454 0.937 1.080 0.472 0.65 T 
335 K 0.936 -0.422 0.937 1.080 0.459 0.85 T 
336 T 0.950 -0.392 0.914 1.090 0.375 0.85 T 
337 G 0.970 -0.357 0.864 1.009 0.458 1.10 T 
338 S 1.000 -0.317 0.770 0.986 0.570 1.10 T 
339 T 1.038 -0.276 0.747 1.064 0.426 0.85 T 
340 G 1.070 -0.209 0.709 1.023 0.404 1.10 T 
341 G 1.099 -0.162 0.746 1.027 0.439 1.10 T 
342 F 1.121 -0.151 0.731 1.070 0.394 0.65 
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343 G 1.135 -0.167 0.743 1.110 0.408 0.65 
344 S 1.138 -0.188 0.847 1.107 0.269 0.65 S 
345 Y 1.126 -0.206 0.920 1.164 0.230 0.65 S 
346 V 1.097 -0.235 0.897 1.189 0.256 0.85 S 
347 A 1.057 -0.263 0.891 1.149 0.195 0.85 S 
348 F 1.011 -0.264 0.980 1.120 0.205 0.85 S 
349 V 0.966 -0.237 1.053 1.051 0.625 0.60 ST 
350 P 0.931 -0.215 1.051 0.947 0.325 0.85 ST 
351 E 0.915 -0.211 1.053 0.964 0.432 0.85 T 
352 K 0.915 -0.255 0.980 0.907 0.326 1.10 T 
353 N 0.932 -0.309 0.989 0.901 0.432 0.90 
354 L 0.964 -0.368 1.044 1.023 0.212 0.65 
355 G 1.004 -0.444 1.049 1.054 0.217 0.40 
356 I 1.038 -0.540 1.059 1.090 0.175 0.40 
357 V 1.055 -0.598 1.114 1.110 0.238 0.40 
358 M 1.043 -0.580 1.057 1.073 0.219 0.60 
359 L 1.011 -0.565 1.153 1.051 0.423 0.60 
360 A 0.964 -0.541 1.131 0.980 0.321 0.85 
361 N 0.906 -0.531 1.104 0.946 0.526 0.85 T 
362 K 0.842 -0.513 0.969 0.899 0.376 1.10 T 
363 S 0.781 -0.520 0.911 0.861 0.310 1.10 T 
364 Y 0.739 -0.577 0.801 0.824 0.732 1.10 T 
365 P 0.723 -0.661 0.803 0.929 0.272 1.10 T 
366 N 0.721 -0.738 0.764 0.960 0.663 1.10 T 
367 P 0.734 -0.761 0.777 1.037 0.302 1.10 T 
368 V 0.757 -0.771 0.880 0.966 0.258 1.10 T 
369 R 0.794 -0.807 0.990 1.003 0.253 1.10 T 
370 V 0.832 -0.821 1.046 1.023 0.215 0.25 
371 E 0.863 -0.814 1.113 1.094 0.334 0.00 S 
372 A 0.880 -0.801 1.120 1.023 0.285 0.25 S 
373 A 0.895 -0.600 1.121 1.089 0.228 0.00 S 
374 W 0.895 -0.600 1.177 1.021 0.266 0.25 S 
375 R 0.887 -0.600 1.177 1.021 0.204 0.25 S 
376 I 0.868 -0.600 1.169 1.003 0.240 0.25 S 
377 L 0.846 -0.600 1.170 1.020 0.263 0.25 S 
378 E 0.824 -0.600 1.210 0.971 0.305 0.25 S 
379 K 0.816 -0.600 1.073 0.830 0.117 0.25 
380 L 0.797 -0.600 1.048 0.668 0.000 0.25 
381 Q 0.791 -0.600 0.857 0.607 0.000 0.50 
382 * 0.830 -0.600 0.000 0.000 0.000 1.40 
 
Figure 18.  Secondary structure of wild-type BLA CMY 2 and mutated variant  
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CHAPTER 4. DISCUSSION 
Reviewing the literature for mutations of bla-cmy-2 at nucleotides 833 and 941 
and amino acids 277 and 313 revealed the following.  In an article published in 2003, 
researchers used “error-prone polymerase Mutazyme in a PCR reaction” in an attempt to 
find potential mutations in CMY-2 that would confer cefepime resistance (Barlow 2003).  
Seven strains expressing mutated CMY-2 were published (Barlow 2003).  One of these 
strains that exhibited cefepime resistance at 32 µg/ml had two mutations at nucleotides 
932 and 941 (Barlow 2003).  Although nucleotide 941 was mutated, it did not cause a 
mutation at amino acid 313 in this study (Barlow 2003).  There was no potential 
explanation given in this article regarding the increase in cefepime resistance.  
A 2009 article may explain some of the increase in cefepime resistance in this 
research strain.  The article described two bla-cmy-2 variants: bla-cmy-33 and bla-cmy-
44 (Doi 2009).  These two variants have “12- to 24-fold increases in the MICs of 
cefepime” (Doi 2009).  The article attributes this increased cefepime resistance to amino 
acid deletions in the sequence in proximity to the H-10 helix or R2 loop (Doi 2009).  The 
structure of the beta-lactamase resulting from these sequence alterations allows the 
enzyme to interact with cephalosporin drugs with larger R2 side chains (Doi 2009).  The 
R2 loop occurs at amino acids 289–307 (Kim 2006).  Although the amino acid mutations 
of this research strain at 277 and 313 are outside of the sequences involved in the loop, 
their proximity and location on either side of the loop spark interest for further 
investigation.  Reviewing the secondary structure of the research strain indicated that a 
structural alteration occurred in the sequence corresponding to the mutation at amino acid 
277. 
 In conclusion, mutations occurring from natural evolution are more likely to 
occur individually (Barlow 2003).  The research strain that displayed cefepime resistance 
contained two mutations, one of which is conserved, implying non-viability under natural 
conditions.  If, however, these mutations were able to occur and persist in nature, it 
would be reasonable that the non-conserved mutation at amino acid 277 would occur 
first.  Perhaps non-conserved mutations in proximity to the H-10 helix are sentinels of 
cefepime resistance.  In any case, bacterial resistance to cefepime does occur, even 
though at present, it is only observed in the laboratory. 
 
51 
 
BIBLIOGRAPHY 
(1) Abraham EP. 1979 Jan-Feb. A glimpse of the early history of the cephalosporins. 
Rev Infect Dis.;1(1):99-105 
(2) Abu Amar M. Al Mamun, Kenneth J. Marians and M. Zafri Humayun. November 
29, 2002. DNA Polymerase III from Escherichia coliCells Expressing mutA 
Mistranslator tRNA Is Error-prone The Journal of Biological Chemistry, 277: 
46319-46327. 
(3) Abdelmadjid Atrih, Gerold Allmaier, Micheal P. Willimson and Simon J. Foster. 
July 1999.  Analysis of Peptidoglycan structure from vegetative Cells of Bacillus 
subtilis168 and Role of PBP 5 in peptidoglycan maturation; Journal of 
Bacteriology,  Vol 181 No 13: p. 3956-3966 
(4) Zeynep Baharoglu, David Bikard, and Didier Mazel.  2010 October. Conjugative 
DNA Transfer Induces the Bacterial SOS Response and Promotes Antibiotic 
Resistance Development through Integron Activation. PLoS Genet.; 6(10): 
e1001165.  
(5) Miriam Barlow and Barry G. Hall. May 2003. Experimental Prediction of the 
Evolution of Cefepime Resistance From CMY-2 ampC Beta-Lactamase. 
Genetics, Vol 164 :pg23-29 
(6) Jeremy M. Berg, John L. Tymoczko and Lubert Stryer. 2007. Biochemistry 6th 
ed.,W. H. Freeman and Company, New York 
(7) A Bauernfeind, I Stemplinger, R Jungwirth and H Giamarellou.  Jan 1996. 
Characterization of the plasmidic beta-lactamase CMY-2, which is responsible for 
cephamycin resistance. Antimicrobial Agents and Chemotherapy, Vol 40, No. 1: 
221-224 
(8) Bush K, Jacoby GA, Medeiros AA.1995. A functional classification scheme for 
beta-lactamases and its correlation with molecular structure. Antimicrob Agents 
Chemother., 39: 1211-33 
(9) K Bush. 1988 January. Beta-lactamase inhibitors from laboratory to clinic; Clin 
Microbiol Rev.; 1(1): 109–123.  
(10) Peter M. J. BurgerstOaFNb, Eugene V. KoonintOc, Elspeth BrufordtOd, Luis 
BlancotOe, Kenneth C. BurtistOf, Michael F. ChristmantOg, William C. 
CopelandtOh, Errol C. Friedbergi, Fumio HanaokatOj, David C. HinkletOk, 
Christopher W. LawrencetOl, Makoto Nakanishim, Haruo OhmoritOn, Louise 
PrakashtOo, Satya PrakashtOo, Claude-Agnes ReynaudtOp, Akio SuginotOq, 
Takeshi TodotOr, Zhigang WangtOs, Jean-Claude WeilltOp and Roger 
WoodgatetOt. November 23, 2001. Eukaryotic DNA Polymerases: Proposal for a 
Revised Nomenclature. The Journal of Biological Chemistry: 276 
(11) H. Carsenti-Etesse, J. D. Cavallo, P. M. Roger, I. Ziha-Zarifi, P. Plesiat, E. 
Garrabé, P. Dellamonica. March 2001. Effect of β-lactam antibiotics on the in 
vitro development of resistance in Pseudomonas aeruginos. Clinical microbiology 
and infection: volume 7, issue 3, 144-151. 
(12) Christian Chalut, Xavier Charpentier, Marie-Hélène Remy, and Jean-Michel 
Masson. January 2001. Differential Responses of Escherichia coli Cells 
Expressing Cytoplasmic Domain Mutants of Penicillin-Binding Protein 1b after 
 
52 
 
Impairment of Penicillin-Binding Proteins 1a and 3. Journal of Bacteriology: Vol. 
183, No. 1,  p. 200-206,  
(13) Marie-Kim Chaveroche, Jean-Marc Ghigo1 and Christophe d’Enfert. A rapid 
method for efficient gene replacement in the filamentous fungus Aspergillus 
nidulans. Oxford JournalsLife Sciences. Nucleic Acids Research: Volume28, 
Issue22Pp. e97.  
(14) Yu Chen, Andrea McReynolds, and Brian K Shoichet. March 2009. Re-
examining the role of Lys67 in class C β-lactamase catalysis. Protein Sci.: 18(3), 
p. 662–669 
(15) Joshua B. Daniels, Douglas R. Call, and Thomas E. Besser. December 2007. 
Molecular Epidemiology of blaCMY-2 Plasmids Carried by Salmonella enterica 
and Escherichia coli Isolates from Cattle in the Pacific Northwest. Applied and 
Environmental Microbiology: Vol. 73, No. 24  p. 8005-8011 
(16) Frank B Dean, John R Nelson, Theresa L Giesler and Roger S Lasken. 2009.  
Rapid Amplification of Plasmid and Phage DNA Using Phi29 DNA polymerase 
and multiple-primed  Rolling Circle Amplification. Genome Res: 11:1095-1099 
(17) Yohei Doi, David L. Paterson, Jennifer M. Adams-Haduch, Hanna E. Sidjabat, 
Alexandra O'Keefe, Andrea Endimiani, and Robert A. Bonomo. 
  
July 2009. 
Reduced Susceptibility to Cefepime among Escherichia coli Clinical Isolates 
Producing Novel Variants of CMY-2 β-Lactamase. Antimicrobial Agents and 
Chemotherapy: Vol. 53, No. 7 p. 3159-3161,  
(18) Andrea Endimiani, Federico Perez and Robert A Bonomo. Dec 2008. Cefepime: a 
reappraisal in an era of increasing antimicrobial resistance. NIH Expert Rev Anti 
Infect Ther.: 6(6): 805-824  
(19) Ekaterina G. Frank and   Roger Woodgate. August 24, 2007.  Increased Catalytic 
Activity and Altered Fidelity of Human DNA Polymerase ι in the Presence of 
Manganese. The Journal of Biological Chemistry: 282, 24689-24696. 
(20) Ryota Fuji, Motomitsu Kitaoka and Kiyoshi Hayashi. 2004. One-step random 
mutagenesis by error-prone rolling circle amplification. Nucleic Acids Res.: 
32(19):e145 
(21) Ryota Fuji, Motomitsu Kitaoka and Kiyoshi Hayashi. 2006. Error-prone rolling 
circle amplification: the simplest random mutagenesis protocol. Natural 
Protocols: 1,2493-2497 
(22) Javier Garau, Walter Wilson, Martin Wood,and Jean Carlet. Oct 2008. Fourth-
generation cephalosporin: a review of in vitro activity, pharmacokinetics, 
pharmacodynamics and clinical utility. Clinical Microbiology and Infection: 
Volume 3, Issue s1, Pg s87-s101 
(23) Giamarellou H. Dec 1999. Fourth generation cephalosporins in the antimicrobial 
chemotherapy of surgical infections. J Chemotherapy: 11(6): pg 486-493. 
(24) Ghosh AS, Chowdhury C, Nelson DE. July 2008. Physiological functions of D-
alanine carboxypeptidases in Escherichia coli. Trends Microbiol.: 16(7):309-17. 
Epub 2008 Jun 5. 
(25) Hamdan S, Bulloch EM, Thompson PR, Beck JL, Yang JY, Crowther JA, Lilley 
PE, Carr PD, Ollis DL, Brown SE, Dixon NE. Apr 2002. Hydrolysis of the 5'-p-
nitrophenyl ester of TMP by the proofreading exonuclease (epsilon) subunit of 
Escherichia coli DNA polymerase III. Biochemistry.: 41(16):5266-75. 
 
53 
 
(26) Hata M, Tanaka Y, Fujii Y, Hoshino T, Neya S . Sep14-17, 2003 Deacylation 
Mechanism of Class C Beta-Lactamase; Interscience Conference on 
Antimicrobial Agents and Chemotherapy (43rd: 2003: Chicago, Ill.). Abstr 
Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents 
Chemother.: 43: abstract no. C1-673.  
(27) M. Hedberg, L. Lindqvist, K. Tunér and C.E. Nord.1992. Effect of clavulanic 
acid, sulbactam and tazobactam on three different β-lactamases from Bacteroides 
uniformis, Clostridium butyricwn and Fusobacterium nucleatum. J. Antimicrob. 
Chemother. 30 (1): 17-25.  
(28) Higurashi Y, Okuzumi K, Yoneyama A and Nakahara K. 1997 Dec. The in Vitro 
Antibacterial Activity of Cefozopran Against Clinically Isolated Bacteria. 
Japanese Journal of Antibiotics, 50(12); 907-916 
(29) Kayo Ikeda, Kazuro Ikawa, Norifumi Morikawa, Hiroki Ohge and Taijiro Sueda. 
2009. Determination of total cefozopran concentrations in human peritoneal fluid 
by HPLC with Cefepime as an internal standard: Comparative pharmacokinetics 
in the fluid and plasma. Journal of Pharmaceutical and Biomedical Analysis  
vol49: 1075-1081 
(30) George A. Jacoby. January 2009. AmpC β-LactamasesClinical. Microbiology 
Reviews , Vol. 22, No. 1: p. 161-182 
(31) Jae Young Kim,Ha ll Jung, Young Jun An, Jung Hun Lee, So Jung Kim, Seok 
Hoon Jeong, Kye Joon Lee, Pann-Ghill Suh, Heung-Soo Lee, Sang Hee Lee, and 
Sun-Shin Cha. 2006.  Structural basis for the extended substrate spectrum of 
CMY-10, a plamid-encoded class C Beta-lactamase.  Molecular Microbiology 
60(4): 907-916  
(32) Kim DJ, King JA, Zuccarelli L, Ferris CF, Koppel GA, Snowdon CT, Ahn CH. 
2009 Aug. Clavulanic acid: a competitive inhibitor of beta-lactamases with novel 
anxiolytic-like activity and minimal side effects. Pharmacol Biochem 
Behav.;93(2):112-20.  
(33) Marie-Frédérique Lartigue, Laurent Poirel, Daniel Aubert, and Patrice Nordmann. 
2006 April.  In Vitro Analysis of ISEcp1B-Mediated Mobilization of Naturally 
Occurring β-Lactamase Gene blaCTX-M of Kluyvera ascorbata .Antimicrob Agents 
Chemother.; 50(4): 1282–1286. 
(34)  Mainardi JL, Fourgeaud M, Hugonnet JE, Dubost L, Brouard JP, Ouazzani J, 
Rice LB, Gutmann L, Arthur MJ.  2005 Nov 18. Novel Peptidoglycan Cross-
Linking Enzyme for a Beta-lactam-resistant Transpeptidation Pathway. Biol 
Chem.280(46): pg38146-38152.  
(35) Hedi Mammeri, Laurent Poirel, Nicolas Fortineau, and Patrice Nordmann. July 
2006. Naturally Occurring Extended-Spectrum Cephalosporinases in Escherichia 
coli. Antimicrobial Agents and Chemotherapy Vol. 50, No. 7: p. 2573–2576 
(36) Bernadette M. Meberg, Avery L. Paulson, Richa Priyadarshini, and Kevin D. 
Young. 2004 December.  Endopeptidase Penicillin-Binding Proteins 4 and 7 Play 
Auxiliary Roles in Determining Uniform Morphology of Escherichia coli. J 
Bacteriol. 186(24): 8326–8336. 
(37) The Merk Manuals online medical library (2009) 
(38) Bartolomé Moya, Andreas Dötsch, Carlos Juan, Jesús Blázquez, Laura Zamorano, 
Susanne Haussler, and Antonio Oliver. 2009 March.  β-Lactam Resistance 
 
54 
 
Response Triggered by Inactivation of a Nonessential Penicillin-Binding Protein. 
PLoS Pathog.; 5(3): e1000353 
(39) Ryuichi Nakano, Ryoichi Okamoto, Yumiko Nakano, Kenichi Kaneko, Naohiro 
Okitsu, Yoshio Hosaka, and Matsuhisa Inoue. 
 
   April 2004. CFE-1, a Novel 
Plasmid-Encoded AmpC ß-Lactamase with an ampR Gene Originating from 
Citrobacter freundii. Antimicrobial Agents and Chemotherapy,  Vol. 48, No. 4: p. 
1151-1158 
(40) David E. Nelson and Kevin D. Young. May 2001. Contributions of PBP 5 and 
DD-Carboxypeptidase Penicillin Binding Proteins to Maintenance of Cell Shape 
in Escherichia coli.  Journal of Bacteriology. Vol. 183, No. 10: p. 3055-3064 
(41) Neu Hc. 1986 Jul-Aug.  Beta-lactam antibiotics: structural relationships affecting 
in vitro activity and pharmacologic properties. Rev Infect Dis; 8 Suppl 3:S237-59 
(42) V. k. Nigam, S. Kundu, and P. Ghosh. 2005. Single-step conversion of 
cephalosporin-c to 7-Aminocephalospranic acid by free and immobilized cells of 
Pseudomonas diminuta.  Applied biochemistry and biotechnology, vol 126, No 1: 
pg 13-21 
(43) Abe Noriyuki,   Komatsu Masaru, Iwasaki Mizuho,   Nagasaka Yoko,   Fukuda 
Saori, Matsuo Shuji,   Shimakawa Koichi. 2005. In vitro activity Agents against 
clinical isolates of Pseudomonas aeruginosa. Japanese Journal of antibiotics, vo 
58, no 5: pg 445-451  
(44) Sridhar Peddi, Robert A. Nicholas, and William G. Gutheil. 2009 June 23. 
Neisseria gonorrhoeae Penicillin-Binding Protein 3 Demonstrates a Pronounced 
Preference for Nε-Acylated Substrates. Biochemistry.; 48(24): 5731–5737.  
(45) Alain Philippon, Guillaume Arlet, and George A. Jacoby. 2002 January. Plasmid-
Determined AmpC-Type β-Lactamases. Antimicrob Agents Chemother.; 46(1): 
1–11  
(46) Reiner R. 1986. Correlation between structure and biological properties of 
cephalosporins: the discovery of ceftriaxone. Drugs Exp Clin Res., 12(4):299-302 
(47) Roche G.  1989 Oct 11. Cefixime, the first oral third-generation cephalosporin. 
Presse Med.; vol 18(32):1541-4 
(48) MA Sirover and LA Loeb. December. 1976. Infidelity of DNA synthesis in vitro: 
screening for potential metal mutagens or carcinogens. Science 24: Vol. 194 no. 
4272 pp. 1434-1436  
(49) Keith A. Stubbs , Misty Balcewich, Brian L. Mark and David J. Vocadlo.  July 
20, 2007.  Small Molecule Inhibitors of a Glycoside Hydrolase Attenuate 
Inducible AmpC-mediated β-Lactam Resistance. The Journal of Biological 
Chemistry,vol 282: 21382-21391 
(50) Sutherland R.J.  1990 Mar. Development of beta-lactamase inhibitors . 
Med.Reprod vol 35(3 Suppl):307-12..  
(51) Joshua D. Tompkins, Jennifer L. Nelson, Jill C. Hazel, Stacy L. Leugers, Jeffrey 
D. Stumpf, and Patricia L. Foster.  June 2003. Error-Prone Polymerase, DNA 
Polymerase IV, Is Responsible for Transient Hypermutation during Adaptive 
Mutation in Escherichia coli. Journal of Bacteriology, Vol. 185, No. 11: pg 3469-
3472, 
(52) Watanabe NA. 1996. Newer antipseudomonal cephalosporins.  J chemother. 1996 
Feb 8 Suppl 2: pg 48-56. 
 
55 
 
(53) Yahav D., Fraser A.,Sarid N.,Leibovici L. 2008 Aug. Is Cefepime Safe?. 
Cleveland Clinic Journal of Medicine: Vol 75 No 8: Pg 585-586 
(54) Richard A. Zakour, Thomas A. Kunkel, and Lawrence A. Loeb.  1981. Metal-
Induced Infidelity of DNA Synthesis. Environmental Health Perspectives Vol. 40: 
pp. 197-205  
 
 
 
